US20030135053A1 - Bicyclic aromatic compounds - Google Patents

Bicyclic aromatic compounds Download PDF

Info

Publication number
US20030135053A1
US20030135053A1 US10/334,978 US33497803A US2003135053A1 US 20030135053 A1 US20030135053 A1 US 20030135053A1 US 33497803 A US33497803 A US 33497803A US 2003135053 A1 US2003135053 A1 US 2003135053A1
Authority
US
United States
Prior art keywords
tetrahydro
naphthyl
acid
pentamethyl
radical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/334,978
Inventor
Jean-Michel Bernardon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/334,978 priority Critical patent/US20030135053A1/en
Publication of US20030135053A1 publication Critical patent/US20030135053A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4986—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • C07C57/50—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid containing condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans

Definitions

  • the invention relates to bicyclic aromatic compounds as novel and useful industrial products. It also relates to the use of these novel compounds in pharmaceutical compositions intended for use in human or veterinary medicine, or alternatively in cosmetic compositions.
  • the compounds according to the invention have pronounced activity in the fields of cell differentiation and cell proliferation, and find applications more particularly in the topical and systemic treatment of dermatological complaints associated with a disorder of keratinization, dermatological (or other) complaints with an inflammatory and/or immunoallergic component, and dermal or epidermal proliferations, these being either benign or malignant.
  • These compounds may also be used in the treatment of degenerative diseases of connective tissue, for combating both light-induced and chronological ageing of the skin and for treating disorders of cicatrization. They moreover find an application in the ophthalmological field, in particular in the treatment of corneopathies.
  • the compounds according to the invention may also be used in cosmetic compositions for body and hair hygiene.
  • R 1 represents
  • Ar represents a radical chosen from the radicals of formulae (a)-(e) below:
  • R 2 and R 3 which may be identical or different, represent
  • R 5 having the meaning given below, it being understood that R 2 and R 3 , taken together, may form with the adjacent aromatic ring a 5- or 6-membered ring optionally substituted with methyl groups and/or optionally interrupted by an oxygen or sulphur atom,
  • R 2 and R 3 cannot at the same time have the meanings (i), (iii) and (iv) mentioned above,
  • R 4 and R 7 which may be identical or different, represent a hydrogen atom, a halogen atom, a linear or branched alkyl radical having from 1 to 20 carbon atoms or a radical —OR 5 ,
  • R 5 represents a hydrogen atom, a lower alkyl radical or a radical —COR 10
  • R 6 represents:
  • R 8 and R 9 which may be identical or different, represent a hydrogen atom or a lower alkyl radical
  • R 10 represents a lower alkyl radical
  • R 11 represents a hydrogen atom, a linear or branched alkyl radical having from 1 to 20 carbon atoms, an alkenyl radical, a mono- or polyhydroxyalkyl radical, an optionally substituted aryl or aralkyl radical, a sugar residue or an amino acid or peptide residue,
  • R′ and R′′ which may be identical or different, represent a hydrogen atom, a lower alkyl radical, a mono- or polyhydroxyalkyl radical, an optionally substituted aryl radical or an amino acid or sugar residue, or alternatively, taken together form a heterocycle.
  • the invention is also directed towards the salts of the compounds of formula (I) when R 1 represents a carboxylic acid function and the geometrical and optical isomers of the said compounds of formula (I).
  • the compounds according to the invention are in the form of salts, they are preferably salts of an alkali metal or alkaline-earth metal, or alternatively of zinc or of an organic amine.
  • the term lower alkyl radical is understood to refer to a radical having from 1 to 12, preferably from 1 to 9, carbon atoms, advantageously the methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl, hexyl, heptyl, nonyl, decyl and dodecyl radicals.
  • linear alkyl radical having from 1 to 20 carbon atoms is understood to refer in particular to the methyl, ethyl, propyl, pentyl, hexyl, octyl, decyl, dodecyl, hexadecyl and octadecyl radicals.
  • branched alkyl radical having from 1 to 20 carbon atoms is understood to refer in particular to the 2-ethylhexyl, 2-methylbutyl, 2-methylpentyl, 1-methylhexyl and 3-methylheptyl radicals.
  • alkyl radicals having at least 3 carbon atoms where the carbon attached to the phenyl radical is substituted with at least two carbon atoms
  • these radicals Preferably, these radicals have not more than 20 carbon atoms, even more preferably not more than 12 carbon atoms.
  • the radical (ii) is the tert-butyl radical.
  • a radical having 2 or 3 carbon atoms in particular a 2-hydroxyethyl, 2-hydroxypropyl or 3-hydroxypropyl radical, is preferred.
  • a radical having from 3 to 6 carbon atoms and from 2 to 5 hydroxyl groups such as the 2,3-dihydroxypropyl, 2,3,4-trihydroxybutyl or 2,3,4,5-tetrahydroxypentyl radicals or the pentaerythritol residue, is preferred.
  • aryl radicals a phenyl radical optionally substituted with at least one halogen atom, a hydroxyl or a nitro function is preferred.
  • the benzyl or phenethyl radical optionally substituted with at least one halogen atom, a hydroxyl or a nitro function is preferred.
  • alkenyl radicals a radical containing from 2 to 5 carbon atoms and having one or more ethylenic unsaturations, more particularly such as the allyl radical, is preferred.
  • sugar residue is understood to refer to a residue derived in particular from glucose, galactose or mannose, or alternatively from glucuronic acid.
  • amino acid residue is understood to refer in particular to a residue derived from lysine, from glycine or from aspartic acid
  • peptide residue is understood to refer more particularly to a dipeptide or tripeptide residue resulting from the combination of amino acids.
  • heterocycle is understood to refer preferably to a piperidino, morpholino, pyrrolidino or piperazino radical optionally S substituted in position 4 with a C 1 -C 6 alkyl or a mono-or polyhydroxyalkyl radical as defined above.
  • radicals R 4 and R 7 represent a halogen atom, this is preferably a fluorine, bromine or chlorine atom.
  • the compounds of formula (I) more particularly preferred are those for which at least one, and preferably all, of the following conditions are satisfied:
  • R 1 represents the radical —COR 6
  • Ar represents the radicals of formula (a) or (d)
  • R 2 and R 3 taken together, form, with the adjacent aromatic ring, a 5- or 6-membered ring optionally substituted with methyl groups and/or optionally interrupted by an oxygen or sulphur atom.
  • the subject of the present invention is also processes for the preparation of the compounds of formula (I), in particular according to the reaction scheme given in FIG. 1.
  • the derivatives of formula (Ia) may be obtained (FIG. 1) from aldehyde or ketone derivatives (5) according to a Horner-type reaction with a lithium or sodium derivative of a phosphonate (7).
  • the carbonyl compounds (5) may be obtained:
  • boronic acid (3) either by a coupling reaction between a boronic acid (3) and a halo derivative (4).
  • This reaction is carried out in the presence of a palladium catalyst, for example tetrakis(triphenylphosphine)-palladium according to the conditions described by N. Miyaura et al., Synthetic Communications (1981) 11(7), 513-519.
  • the boronic acid derivative (3) may be obtained, for example, from the halo derivative (1) by conversion into the lithium reagent (2), followed by reaction with trimethyl borate and hydrolysis.
  • the compounds of formula (Ib) may be obtained (FIG. 1) from the acetylenic derivative (6) by reaction with n-butyllithium and then carboxylation in the presence of CO 2 .
  • the acetylenic compounds (6) may be obtained either:
  • aldehyde derivatives (5) when R 8 is a hydrogen atom, by reaction with carbon tetrabromide and triphenylphosphine in-order to give a 2′,2′-dibromostyrene derivative which is converted into acetylenic derivative by a non-nucleophilic base such as n-butyllithium, in an aprotic solvent such as tetrahydrofuran.
  • R 1 represents the radical —COOH
  • the compounds are prepared by protecting R 1 with a protecting group of alkyl, allylic, benzylic or tert-butyl type.
  • the subject of the present invention is also, as medicinal product, the compounds of formula (I) as defined above.
  • Some of these compounds are active in a test which consists in identifying molecules that are RXR agonists, as described in French patent application No. 95/07301 filed on Jun. 19, 1995 by the Applicant.
  • This test comprises the following steps: (i) a sufficient amount of a compound which is an active ligand of at least one receptor of the staroidal/thyroidal receptor superfamily, other than a ligand which is specific for the RXR receptors, and which can heterodimerize with RXRs, such as an RAR-agonist molecule, is applied topically to part of the skin of a mammal, (ii) a molecule capable of exhibiting RXR-agonist activity is administered systemically or topically to this same part of the mammal's skin, before, during or after step (i), and (iii) the response on that part of the mammal's skin thus treated is evaluated.
  • ⁇ -hydroxy or ⁇ -keto acids or derivatives thereof is understood to refer, for example, to lactic acid, malic acid, citric acid, glycolic acid, mandelic acid, tartaric acid, glyceric acid or ascorbic acid or salts, amides or esters thereof.
  • ion-channel blockers is understood to refer, for example, to Minoxidil (2,4-diamino-6-piperidinopyrimidine 3-oxide) and derivatives thereof.
  • the subject of the present invention is also medicinal compositions containing at least one compound of formula (I) as defined above, one of the optical or geometric isomers thereof or one of the salts thereof.
  • the subject of the present invention is thus a novel medicinal composition intended in particular for treating the abovementioned complaints, and which is characterized in that it comprises, in a pharmaceutically acceptable support which is compatible with the mode of administration selected for this composition, at least one compound of formula (I), one of the optical or geometric isomers thereof or one of the salts thereof.
  • the compounds according to the invention may be administered enterally, parenterally, topically or ocularly.
  • the medicinal products may be in the form of tablets, gelatin capsules, sugar-coated tablets, syrups, suspensions, solutions, powders, granules, emulsions, microspheres or nanospheres or polymeric or lipid vesicles which allow controlled release.
  • the compositions may be in the form of solutions or suspensions for infusion or for injection.
  • the compounds according to the invention are generally administered at a daily dose of about 0.01 mg/kg to 100 mg/kg of body weight, taken in 1 to 3 doses.
  • the pharmaceutical compositions based on compounds according to the invention are more particularly intended for treating the skin and mucous membranes and may, in this case, be in the form of ointments, creams, milks, salves, powders, impregnated pads, solutions, gels, sprays, lotions or suspensions. They may also be in the form of microspheres or nanospheres or polymeric or lipid vesicles or polymeric patches and hydrogels which allow controlled release. These topical-route compositions may moreover be either in anhydrous form or in an aqueous form, depending on the clinical indication.
  • compositions for topical or ocular use contain at least one compound of formula (I) defined above, or one of the optical or geometric isomers thereof, or alternatively one of the salts thereof, at a concentration preferably of between 0.001% and 5% by weight relative to the total weight of the composition.
  • the compounds of formula (I) according to the invention also find an application in the cosmetic field, in particular in body and hair hygiene and especially for treating skin-types with a tendency towards acne, for promoting the regrowth of the hair, for combating hair loss, for controlling the greasy appearance of the skin or the hair, in protection against the harmful effects of sunlight or in the treatment of physiologically dry skin-types, and for preventing and/or combating light-induced or chronological ageing.
  • the compounds according to the invention may also advantageously be employed in combination with other compounds having retinoid-type activity, with D vitamins or derivatives thereof, with corticosteroids, with anti-free-radical agents, ⁇ -hydroxy or ⁇ -keto acids or derivatives thereof, or alternatively with ion-channel blockers, all of these different products being as defined above.
  • the present invention is this also directed towards a cosmetic composition which is characterized in that it comprises, in a cosmetically acceptable support which is suitable for topical application, at least one compound of formula (I) as defined above, or one of the optical or geometric isomers thereof or one of the salts thereof, it being possible in particular for this cosmetic composition to be in the form of a cream, a milk, a lotion, a gel, microspheres or nanospheres or polymeric or lipid vesicles, a soap or a shampoo.
  • a cosmetic composition which is characterized in that it comprises, in a cosmetically acceptable support which is suitable for topical application, at least one compound of formula (I) as defined above, or one of the optical or geometric isomers thereof or one of the salts thereof, it being possible in particular for this cosmetic composition to be in the form of a cream, a milk, a lotion, a gel, microspheres or nanospheres or polymeric or lipid vesicles, a soap or a shampoo.
  • the concentration of compound of formula (I) in the cosmetic compositions according to the invention is advantageously between 0.001% and 3% by weight relative to the composition as a whole.
  • the medicinal and cosmetic compositions according to the invention may also contain inert additives or even pharmacodynamically or cosmetically active additives or combinations of these additives and, in particular, wetting agents; depigmenting agents such as hydroquinone, azelaic acid, caffeic acid or kojic acid; emollients; moisturizing agents such as glycerol, PEG 400, thiamorpholinone and derivatives thereof, or urea; anti-seborrhoea or anti-acne agents such as S-carboxymethylcysteine, S-benzylcysteamine, the salts and the derivatives thereof, or benzoyl peroxide; antibiotics such as erythromycin and esters thereof, neomycin, clindamycin and esters thereof, and tetracyclines; antifungal agents such as ketoconazole or 4,5-polymethylene-3-isothiazolidones; agents for promoting the regrowth of the hair,
  • compositions according to the invention may also contain flavour-enhancing agents, preserving agents such as para-hydroxybenzoic acid esters, stabilizing agents, moisture regulators, pH regulators, osmotic pressure modifiers, emulsifying agents, UV-A and UV-B screening agents, and antioxidants such as ⁇ -tocopherol, butylhydroxyanisole or butylhydroxytoluene.
  • a solution of 2 g (8.2 mmol) of 3-tert-butyl-4-methoxybromobenzene is added dropwise to a suspension of 300 mg (12 mmol) of magnesium in 10 ml of THF. Once the addition is complete, the mixture is refluxed for one hour. At room temperature, 1.35 g (9.9 mmol) of anhydrous zinc chloride are added and the mixture is stirred for one hour. 1.2 g (5.5 mmol) of methyl 5-bromo-2-thiophenecarboxylate and 60 mg (0.12 mmol) of the NiCl 2 /DPPE complex are then added successively and the mixture is left stirring at room temperature for 12 hours.
  • the reaction medium is poured into ice-water and extracted with ethyl ether and the organic phase is separated out after settling has taken place, dried over magnesium sulphate and evaporated.
  • the residue obtained is chromatographed on a column of silica eluted with a mixture of hexane and dichloromethane (50/50% by volume). After evaporation of the solvents, 1.56 g (93%) of the expected methyl ester are collected, with a melting point of 94-5° C.
  • the reaction medium is stirred at room temperature for four hours and is then poured into water and extracted with ethyl ether, and the organic phase is separated out after settling has taken place, dried over magnesium sulphate and evaporated.
  • the residue obtained is purified by chromatography on a column of silica eluted with a mixture of dichloromethane and hexane (30/70% by volume); 1.88 g (100%) of the expected ethyl ester are collected, in the form of a brown oil.
  • reaction medium is extracted with ethyl ether and the organic phase is separated out after settling has taken place, dried over magnesium sulphate and evaporated. 3.79 g (100%) of the expected boronic acid are collected, which is used in its present state for the rest of the synthesis.
  • the reaction medium is evaporated to dryness, the residue is taken up in water and ethyl ether and the organic phase is separated out after settling has taken place, dried over magnesium sulphate and evaporated.
  • the residue is purified by chromatography on a column of silica eluted with a mixture of ethyl acetate and heptane (10/90% by volume). 3.53 g (69%) of ethyl 2-(3-tert-butyl-4-methoxyphenyl)-4-thiophenecarboxylate are obtained.
  • Example 1(b) In a similar manner to Example 1(b), starting with 3.5 g (11 mmol) of ethyl 2-(3-tert-butyl-4-methoxyphenyl)-4-thiophenecarboxylate, 3.2 g (100%) of the expected alcohol are obtained in the form of a brown oil.
  • reaction medium is extracted with ethyl acetate and the organic phase is separated out after settling has taken place, washed twice with 500 ml of hydrochloric acid (1 N), dried over magnesium sulphate and evaporated. 83 g (95%) of the expected boronic acid are collected.
  • the reaction medium is cooled and filtered and the solid is washed with bicarbonate solution and then with ethyl acetate.
  • the solid obtained is recrystallized from ethanol and 7 g (50%) of the expected aldehyde are collected, with a melting point of 104-5° C.
  • the reaction medium is poured into water and extracted with ethyl acetate, and the organic phase is separated out after settling has taken place, dried over magnesium sulphate and evaporated.
  • the residue obtained is purified by chromatography on a column of silica eluted with a mixture of dichloromethane and heptane (70/30). After evaporation of the solvents, 600 mg (44%) of the expected product are collected.
  • the reaction medium is poured into saturated ammonium chloride solution and adjusted to pH 1 with hydrochloric acid, the mixture is extracted with ethyl acetate and the organic phase is separated out after settling has taken place, dried over magnesium sulphate and evaporated.
  • the residue obtained is purified by chromatography on a column of silica eluted with a mixture of dichloromethane and methanol (95/5). After evaporation of the solvents, 80 mg (12%) of 3-(5,6,7,8-tetrahydro-5,5,8,8-tetra-methyl-2-naphthyl)phenylpropiolic acid are collected, with a melting point of 164-5° C.
  • reaction medium is poured into water and extracted with ethyl ether, and the organic phase is separated out after settling has taken place, dried over magnesium sulphate and evaporated. 7.3 g (99%) of the expected product are collected in the form of an oil which crystallizes slowly. Melting point 77-8° C.
  • A- ORAL ROUTE (a) 0.2 g tablet Compoud of Example 1 0.001 g Starch 0.114 g Dicalcium phosphate 0.020 g Silica 0.020 g Lactose 0.030 g Talc 0.010 g Magnesium stearate 0.005 g (b) Drinkable suspension in 5 ml ampoules Compound of Example 3 0.001 g Glycerol 0.500 g 70% Sorbitol 0.500 g Sodium saccharinate 0.010 g Methyl para-hydroxybenzoate 0.040 g Flavouring qs Purified water qs 5 ml (c) 0.8 g tablet Compound of Example 5 0.500 g Pregelatinized starch 0.100 g Microcrystalline cellulose 0.115 g Lactose 0.075 g Magnesium stearate 0.010 g (d) Drinkable suspension in 10 ml ampoules

Abstract

The invention relates to novel bicyclic aromatic compounds which have the general formula (I):
Figure US20030135053A1-20030717-C00001
as well as to the use of these compounds in pharmaceutical compositions intended for use in human or veterinary medicine (dermatological, rheumatic, respiratory, cardiovascular and ophthalmological complaints in particular), or alternatively in cosmetic compositions.

Description

  • The invention relates to bicyclic aromatic compounds as novel and useful industrial products. It also relates to the use of these novel compounds in pharmaceutical compositions intended for use in human or veterinary medicine, or alternatively in cosmetic compositions. [0001]
  • The compounds according to the invention have pronounced activity in the fields of cell differentiation and cell proliferation, and find applications more particularly in the topical and systemic treatment of dermatological complaints associated with a disorder of keratinization, dermatological (or other) complaints with an inflammatory and/or immunoallergic component, and dermal or epidermal proliferations, these being either benign or malignant. These compounds may also be used in the treatment of degenerative diseases of connective tissue, for combating both light-induced and chronological ageing of the skin and for treating disorders of cicatrization. They moreover find an application in the ophthalmological field, in particular in the treatment of corneopathies. [0002]
  • The compounds according to the invention may also be used in cosmetic compositions for body and hair hygiene. [0003]
  • The compounds according to the invention may be represented by the general formula (I) below: [0004]
    Figure US20030135053A1-20030717-C00002
  • in which: [0005]
  • R[0006] 1 represents
  • (i) the —CH[0007] 3 radical
  • (ii) the radical —CH[0008] 2OR5
  • (iii) the radical —COR[0009] 6
  • R[0010] 5 and R6 having the meaning given below
  • Ar represents a radical chosen from the radicals of formulae (a)-(e) below: [0011]
    Figure US20030135053A1-20030717-C00003
  • R[0012] 5 and R7 having the meaning given below,
  • X represents [0013]
    Figure US20030135053A1-20030717-C00004
  • R[0014] 8 and R9 having the meanings given below
  • R[0015] 2 and R3, which may be identical or different, represent
  • (i) a hydrogen atom, [0016]
  • (ii) an alkyl radical having at least 3 carbon atoms, among which the carbon attached to the phenyl radical is substituted with at least two carbon atoms, [0017]
  • (iii) a radical —OR[0018] 5,
  • (iv) a radical —SR[0019] 5,
  • R[0020] 5 having the meaning given below, it being understood that R2 and R3, taken together, may form with the adjacent aromatic ring a 5- or 6-membered ring optionally substituted with methyl groups and/or optionally interrupted by an oxygen or sulphur atom,
  • and it being understood that R[0021] 2 and R3 cannot at the same time have the meanings (i), (iii) and (iv) mentioned above,
  • R[0022] 4 and R7, which may be identical or different, represent a hydrogen atom, a halogen atom, a linear or branched alkyl radical having from 1 to 20 carbon atoms or a radical —OR5,
  • R[0023] 5 represents a hydrogen atom, a lower alkyl radical or a radical —COR10
  • R[0024] 10 having the meaning given below,
  • R[0025] 6 represents:
  • (a) a hydrogen atom [0026]
  • (b) a lower alkyl radical [0027]
  • (c) a radical of formula: [0028]
    Figure US20030135053A1-20030717-C00005
  • R′ and R″ having the meaning given below, [0029]
  • (d) a radical —OR[0030] 11
  • R[0031] 11 having the meaning given below,
  • R[0032] 8 and R9, which may be identical or different, represent a hydrogen atom or a lower alkyl radical,
  • R[0033] 10 represents a lower alkyl radical,
  • R[0034] 11 represents a hydrogen atom, a linear or branched alkyl radical having from 1 to 20 carbon atoms, an alkenyl radical, a mono- or polyhydroxyalkyl radical, an optionally substituted aryl or aralkyl radical, a sugar residue or an amino acid or peptide residue,
  • R′ and R″, which may be identical or different, represent a hydrogen atom, a lower alkyl radical, a mono- or polyhydroxyalkyl radical, an optionally substituted aryl radical or an amino acid or sugar residue, or alternatively, taken together form a heterocycle. [0035]
  • The invention is also directed towards the salts of the compounds of formula (I) when R[0036] 1 represents a carboxylic acid function and the geometrical and optical isomers of the said compounds of formula (I).
  • When the compounds according to the invention are in the form of salts, they are preferably salts of an alkali metal or alkaline-earth metal, or alternatively of zinc or of an organic amine. [0037]
  • According to the present invention, the term lower alkyl radical is understood to refer to a radical having from 1 to 12, preferably from 1 to 9, carbon atoms, advantageously the methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl, hexyl, heptyl, nonyl, decyl and dodecyl radicals. [0038]
  • The expression linear alkyl radical having from 1 to 20 carbon atoms is understood to refer in particular to the methyl, ethyl, propyl, pentyl, hexyl, octyl, decyl, dodecyl, hexadecyl and octadecyl radicals. [0039]
  • The expression branched alkyl radical having from 1 to 20 carbon atoms is understood to refer in particular to the 2-ethylhexyl, 2-methylbutyl, 2-methylpentyl, 1-methylhexyl and 3-methylheptyl radicals. [0040]
  • Among the alkyl radicals having at least 3 carbon atoms, where the carbon attached to the phenyl radical is substituted with at least two carbon atoms, mention may be made of the tert-butyl, isopropyl, 1,1-dimethylhexyl and 1,1-dimethyldecyl radical. Preferably, these radicals have not more than 20 carbon atoms, even more preferably not more than 12 carbon atoms. Advantageously, the radical (ii) is the tert-butyl radical. [0041]
  • Among the monohydroxyalkyl radicals, a radical having 2 or 3 carbon atoms, in particular a 2-hydroxyethyl, 2-hydroxypropyl or 3-hydroxypropyl radical, is preferred. [0042]
  • Among the polyhydroxyalkyl radicals, a radical having from 3 to 6 carbon atoms and from 2 to 5 hydroxyl groups, such as the 2,3-dihydroxypropyl, 2,3,4-trihydroxybutyl or 2,3,4,5-tetrahydroxypentyl radicals or the pentaerythritol residue, is preferred. [0043]
  • Among the aryl radicals, a phenyl radical optionally substituted with at least one halogen atom, a hydroxyl or a nitro function is preferred. [0044]
  • Among the aralkyl radicals, the benzyl or phenethyl radical optionally substituted with at least one halogen atom, a hydroxyl or a nitro function is preferred. [0045]
  • Among the alkenyl radicals, a radical containing from 2 to 5 carbon atoms and having one or more ethylenic unsaturations, more particularly such as the allyl radical, is preferred. [0046]
  • The term sugar residue is understood to refer to a residue derived in particular from glucose, galactose or mannose, or alternatively from glucuronic acid. [0047]
  • The term amino acid residue is understood to refer in particular to a residue derived from lysine, from glycine or from aspartic acid, and the term peptide residue is understood to refer more particularly to a dipeptide or tripeptide residue resulting from the combination of amino acids. [0048]
  • Lastly, the term heterocycle is understood to refer preferably to a piperidino, morpholino, pyrrolidino or piperazino radical optionally S substituted in [0049] position 4 with a C1-C6 alkyl or a mono-or polyhydroxyalkyl radical as defined above.
  • When the radicals R[0050] 4 and R7 represent a halogen atom, this is preferably a fluorine, bromine or chlorine atom.
  • Among the compounds of formula (I) above which fall within the scope of the present invention, mention may be made in particular of the following: [0051]
  • 5-(3-tert-Butyl-4-methoxyphenyl)-2-thiophene-acrylic acid, [0052]
  • 5-(3-tert-Butyl-4-methoxyphenyl)-2-thiophene-propiolic acid, [0053]
  • 2-(3-tert-Butyl-4-methoxyphenyl)-4-thiophene-acrylic acid, [0054]
  • 4-(3-tert-Butyl-4-methoxyphenyl)-2-thiophene-acrylic acid, [0055]
  • 5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiopheneacrylic acid, [0056]
  • 4-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiopheneacrylic acid, [0057]
  • 4-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-thiopheneacrylic acid, [0058]
  • 5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiophenepropiolic acid, [0059]
  • 3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylpropiolic acid, [0060]
  • N-Methyl-4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-pyrroleacrylic acid, [0061]
  • 3-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid, [0062]
  • N-Methyl-4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-pyrroleacrylic acid, [0063]
  • 4-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-pyrroleacrylic acid, [0064]
  • 3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid, [0065]
  • 3-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylpropiolic acid, [0066]
  • 2-Methoxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid, [0067]
  • 2-Propyloxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid, [0068]
  • 2-Heptyloxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid, [0069]
  • 2-Methoxymethoxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid, [0070]
  • 2-Hydroxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid, [0071]
  • 3-(3-Methoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid, [0072]
  • 3-(3-Propyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid, [0073]
  • 3-(3-Heptyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid, [0074]
  • 3-(3-Methoxymethoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid, [0075]
  • 3-(3-Hydroxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid, [0076]
  • 3-(4,4,7-Trimethylthiochroman-6-yl)-phenylacrylic acid, [0077]
  • N-Ethyl-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylamide, [0078]
  • N-(4-Hydroxyphenyl)-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylamide, [0079]
  • 3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid morpholide, [0080]
  • Ethyl 3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylate, [0081]
  • 3-[3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenyl]but-2-enoic acid, [0082]
  • 4-Methoxymethoxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid, [0083]
  • 4-Hydroxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid, [0084]
  • 4-Methoxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid, [0085]
  • 4-Propyloxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid, [0086]
  • 4-Heptyloxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid, [0087]
  • 3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenyl]acrolein, [0088]
  • 3-[3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenyl]prop-2-en-1-ol, [0089]
  • cis-3-[3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenyl]but-2-enoic acid, [0090]
  • cis-3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid, [0091]
  • 5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-3-pyridineacrylic acid, [0092]
  • 3-(3-Butyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid, [0093]
  • 6-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-pyridineacrylic acid. [0094]
  • According to the present invention, the compounds of formula (I) more particularly preferred are those for which at least one, and preferably all, of the following conditions are satisfied: [0095]
  • R[0096] 1 represents the radical —COR6
  • Ar represents the radicals of formula (a) or (d) [0097]
  • X represents the radical [0098]
    Figure US20030135053A1-20030717-C00006
  • R[0099] 2 and R3, taken together, form, with the adjacent aromatic ring, a 5- or 6-membered ring optionally substituted with methyl groups and/or optionally interrupted by an oxygen or sulphur atom.
  • The subject of the present invention is also processes for the preparation of the compounds of formula (I), in particular according to the reaction scheme given in FIG. 1. [0100]
  • Thus, the derivatives of formula (Ia) may be obtained (FIG. 1) from aldehyde or ketone derivatives (5) according to a Horner-type reaction with a lithium or sodium derivative of a phosphonate (7). The carbonyl compounds (5) may be obtained: [0101]
  • either by a coupling reaction between a boronic acid (3) and a halo derivative (4). This reaction is carried out in the presence of a palladium catalyst, for example tetrakis(triphenylphosphine)-palladium according to the conditions described by N. Miyaura et al., Synthetic Communications (1981) 11(7), 513-519. The boronic acid derivative (3) may be obtained, for example, from the halo derivative (1) by conversion into the lithium reagent (2), followed by reaction with trimethyl borate and hydrolysis. [0102]
  • or by a coupling reaction between a zinc derivative (8) and a halogenated ester derivative (9) in the presence of a catalyst, for example a palladium or a nickel derivative (NiCl[0103] 2 dppe), followed by conversion of the ester function (10) into alcohol (11) and oxidation to aldehyde (5).
  • The compounds of formula (Ib) may be obtained (FIG. 1) from the acetylenic derivative (6) by reaction with n-butyllithium and then carboxylation in the presence of CO[0104] 2. The acetylenic compounds (6) may be obtained either:
  • from aldehyde derivatives (5) (when R[0105] 8 is a hydrogen atom), by reaction with carbon tetrabromide and triphenylphosphine in-order to give a 2′,2′-dibromostyrene derivative which is converted into acetylenic derivative by a non-nucleophilic base such as n-butyllithium, in an aprotic solvent such as tetrahydrofuran.
  • from ketone derivatives (5) (when R[0106] 8 is a lower alkyl) by a reaction sequence comprising treatment with a base such as lithium diisopropylamide and then with a dialkyl phosphate chloride and again with lithium diisopropylamide.
  • When R[0107] 1 represents the radical —COOH, the compounds are prepared by protecting R1 with a protecting group of alkyl, allylic, benzylic or tert-butyl type.
  • The passage to the free form may be carried out: [0108]
  • in the case of an alkyl protecting group, using sodium hydroxide or lithium hydroxide in an alcoholic solvent such as methanol, or in THF. [0109]
  • in the case of an allylic protecting group, using a catalyst such as certain transition metal complexes in the presence of a secondary amine such as morpholine. [0110]
  • in the case of a benzylic protecting group, by debenzylation in the presence of hydrogen using a catalyst such as palladium-on-charcoal. [0111]
  • in the case of a protecting group of tert-butyl type, using trimethylsilyl iodide. [0112]
  • The subject of the present invention is also, as medicinal product, the compounds of formula (I) as defined above. [0113]
  • Some of these compounds are active in a test which consists in identifying molecules that are RXR agonists, as described in French patent application No. 95/07301 filed on Jun. 19, 1995 by the Applicant. This test comprises the following steps: (i) a sufficient amount of a compound which is an active ligand of at least one receptor of the staroidal/thyroidal receptor superfamily, other than a ligand which is specific for the RXR receptors, and which can heterodimerize with RXRs, such as an RAR-agonist molecule, is applied topically to part of the skin of a mammal, (ii) a molecule capable of exhibiting RXR-agonist activity is administered systemically or topically to this same part of the mammal's skin, before, during or after step (i), and (iii) the response on that part of the mammal's skin thus treated is evaluated. Thus, the response to a topical application, to a Mammal's ear, of an RAR-agonist molecule, which corresponds to an increase in the thickness of this ear, may be increased by the systemic or topical administration of an RXR-agonist molecule. Some of the compounds according to the invention are also active in the test of differentiation of mouse embryonic teratocarcinoma cells (F9) (Cancer Research 43, pp. 5268, 1983) and/or in the test of inhibition of ornithine decarboxylase after induction with TPA in mice (Cancer Research 38, pp. 793-801, 1978). These tests show the activities of these compounds in the fields of cell differentiation and cell proliferation respectively. [0114]
  • The compounds according to the invention are particularly suitable in the following fields of treatment: [0115]
  • 1) For treating dermatological complaints associated with a keratinization disorder which has a bearing on differentiation and on proliferation, in particular for treating common acne, comedones, polymorphonuclear leukocytes, rosacea, nodulocystic acne, acne conglobata, senile acne and secondary acnes such as solar, medication-related or profession-related acne. [0116]
  • 2) For treating other types of keratinization disorder, in particular ichthyosis, ichthyosiform states, Darier's disease, palmoplantar keratoderma, leucoplasias and leucoplasiform states, and cutaneous or mucous (buccal) lichen. [0117]
  • 3) For treating other dermatological complaints associated with a keratinization disorder with an inflammatory and/or immunoallergic component and, in particular, all forms of psoriasis, whether it is cutaneous, mucous or ungual psoriasis and even psoriatic rheumatism, or alternatively cutaneous atopy, such as eczema or respiratory atopy or alternatively gingival hypertrophy; the compounds may also be used for some inflammatory complaints which show no keratinization disorder, [0118]
  • 4) For treating all dermal or epidermal hyperproliferations, whether benign or malignant and whether they are of viral origin or otherwise, such as common warts, flat warts and verruciform epidermodysplasia, it being possible for the oral or florid papillomatoses and the hyperproliferations to be induced by ultraviolet radiation, in particular in the case of basocellular and spinocellular epithelioma, [0119]
  • 5) For treating other dermatological disorders such as bullosis and collagen diseases, [0120]
  • 6) For treating certain ophthalmological disorders, in particular corneopathies, [0121]
  • 7) For repairing or combating ageing of the skin, whether this is light-induced or chronological ageing, or for reducing actinic keratoses and pigmentations, or any pathologies associated with chronological or actinic ageing, [0122]
  • 8) For preventing or curing the stigmata of epidermal and/or dermal atrophy induced by local or systemic corticosteroids, or any other form of cutaneous atrophy, [0123]
  • 9) For preventing or treating cicatrization disorders or for preventing or repairing vibices, [0124]
  • 10) For combating disorders of sebaceous functioning such as the hyperseborrhoea of acne or simple seborrhoea, [0125]
  • 11) In the treatment or prevention of cancerous or precancerous states, [0126]
  • 12) In the treatment of inflammatory complaints such as arthritis, [0127]
  • 13) In the treatment of any general or skin complaint of viral origin, [0128]
  • 14) In the prevention or treatment of alopecia, [0129]
  • 15) In the treatment of dermatological or general complaints having an immunological component, [0130]
  • 16) In the treatment of complaints of the cardiovascular system such as arteriosclerosis or hypertension, as well as insulin-independent diabetes, [0131]
  • 17) In the treatment of skin disorders caused by exposure to UV radiation. [0132]
  • In the therapeutic fields mentioned above, the compounds according to the invention may advantageously be employed in combination with other compounds having retinoid-type activity, with D vitamins or derivatives thereof, with corticosteroids, with anti-free-radical agents, α-hydroxy or α-keto acids or derivatives thereof, or alternatively with ion-channel blockers. The expression D vitamins or derivatives thereof is understood to refer, for example, to vitamin D[0133] 2 or D3 derivatives and in particular 1,25-dihydroxy vitamin D3. The expression anti-free-radical agent is understood to refer, for example, to α-tocopherol, superoxide dismutase, ubiquinol or certain metal-chelating agents. The expression α-hydroxy or α-keto acids or derivatives thereof is understood to refer, for example, to lactic acid, malic acid, citric acid, glycolic acid, mandelic acid, tartaric acid, glyceric acid or ascorbic acid or salts, amides or esters thereof. Lastly, the expression ion-channel blockers is understood to refer, for example, to Minoxidil (2,4-diamino-6-piperidinopyrimidine 3-oxide) and derivatives thereof.
  • The subject of the present invention is also medicinal compositions containing at least one compound of formula (I) as defined above, one of the optical or geometric isomers thereof or one of the salts thereof. [0134]
  • The subject of the present invention is thus a novel medicinal composition intended in particular for treating the abovementioned complaints, and which is characterized in that it comprises, in a pharmaceutically acceptable support which is compatible with the mode of administration selected for this composition, at least one compound of formula (I), one of the optical or geometric isomers thereof or one of the salts thereof. [0135]
  • The compounds according to the invention may be administered enterally, parenterally, topically or ocularly. [0136]
  • Via the enteral route, the medicinal products may be in the form of tablets, gelatin capsules, sugar-coated tablets, syrups, suspensions, solutions, powders, granules, emulsions, microspheres or nanospheres or polymeric or lipid vesicles which allow controlled release. Via the parenteral route, the compositions may be in the form of solutions or suspensions for infusion or for injection. [0137]
  • The compounds according to the invention are generally administered at a daily dose of about 0.01 mg/kg to 100 mg/kg of body weight, taken in 1 to 3 doses. [0138]
  • Via the topical route, the pharmaceutical compositions based on compounds according to the invention are more particularly intended for treating the skin and mucous membranes and may, in this case, be in the form of ointments, creams, milks, salves, powders, impregnated pads, solutions, gels, sprays, lotions or suspensions. They may also be in the form of microspheres or nanospheres or polymeric or lipid vesicles or polymeric patches and hydrogels which allow controlled release. These topical-route compositions may moreover be either in anhydrous form or in an aqueous form, depending on the clinical indication. [0139]
  • Via the ocular route, they are mainly eyedrops. [0140]
  • The compositions for topical or ocular use contain at least one compound of formula (I) defined above, or one of the optical or geometric isomers thereof, or alternatively one of the salts thereof, at a concentration preferably of between 0.001% and 5% by weight relative to the total weight of the composition. [0141]
  • The compounds of formula (I) according to the invention also find an application in the cosmetic field, in particular in body and hair hygiene and especially for treating skin-types with a tendency towards acne, for promoting the regrowth of the hair, for combating hair loss, for controlling the greasy appearance of the skin or the hair, in protection against the harmful effects of sunlight or in the treatment of physiologically dry skin-types, and for preventing and/or combating light-induced or chronological ageing. [0142]
  • In the cosmetic field, the compounds according to the invention may also advantageously be employed in combination with other compounds having retinoid-type activity, with D vitamins or derivatives thereof, with corticosteroids, with anti-free-radical agents, α-hydroxy or α-keto acids or derivatives thereof, or alternatively with ion-channel blockers, all of these different products being as defined above. [0143]
  • The present invention is this also directed towards a cosmetic composition which is characterized in that it comprises, in a cosmetically acceptable support which is suitable for topical application, at least one compound of formula (I) as defined above, or one of the optical or geometric isomers thereof or one of the salts thereof, it being possible in particular for this cosmetic composition to be in the form of a cream, a milk, a lotion, a gel, microspheres or nanospheres or polymeric or lipid vesicles, a soap or a shampoo. [0144]
  • The concentration of compound of formula (I) in the cosmetic compositions according to the invention is advantageously between 0.001% and 3% by weight relative to the composition as a whole. [0145]
  • The medicinal and cosmetic compositions according to the invention may also contain inert additives or even pharmacodynamically or cosmetically active additives or combinations of these additives and, in particular, wetting agents; depigmenting agents such as hydroquinone, azelaic acid, caffeic acid or kojic acid; emollients; moisturizing agents such as glycerol, PEG 400, thiamorpholinone and derivatives thereof, or urea; anti-seborrhoea or anti-acne agents such as S-carboxymethylcysteine, S-benzylcysteamine, the salts and the derivatives thereof, or benzoyl peroxide; antibiotics such as erythromycin and esters thereof, neomycin, clindamycin and esters thereof, and tetracyclines; antifungal agents such as ketoconazole or 4,5-polymethylene-3-isothiazolidones; agents for promoting the regrowth of the hair, such as minoxidil (2,4-diamino-6-piperidinopyrimidine 3-oxide) and derivatives thereof, diazoxide (7-chloro-3-methyl-1,2,4-benzothiadiazine 1,1-dioxide) and phenytoin (5,4-diphenylimidazolidine-2,4-dione); non-steroidal anti-inflammatory agents; carotenoids and, in particular, b-carotene; anti-psoriatic agents such as anthraline and derivatives thereof and, lastly, eicosa-5,8,11,14-tetraynoic acid and eicosa-5,8,11-triynoic acid, the esters and the amides thereof. [0146]
  • The compositions according to the invention may also contain flavour-enhancing agents, preserving agents such as para-hydroxybenzoic acid esters, stabilizing agents, moisture regulators, pH regulators, osmotic pressure modifiers, emulsifying agents, UV-A and UV-B screening agents, and antioxidants such as α-tocopherol, butylhydroxyanisole or butylhydroxytoluene. [0147]
  • Several examples of the production of active compounds of formula (I) according to the invention, as well as various solid formulations based on such compounds, will now be given by way of illustration and with no limitation. In the preceding description and the following examples, percentages are given by weight unless otherwise stated.[0148]
    • EXAMPLE 1 5-(3-tert-Butyl-4-methoxyphenyl)-2-thiophene-acrylic acid
  • (a) Methyl 5-(3-tert-butyl-4-methoxyphenyl)-2-thiophenecarboxylate [0149]
  • A solution of 2 g (8.2 mmol) of 3-tert-butyl-4-methoxybromobenzene is added dropwise to a suspension of 300 mg (12 mmol) of magnesium in 10 ml of THF. Once the addition is complete, the mixture is refluxed for one hour. At room temperature, 1.35 g (9.9 mmol) of anhydrous zinc chloride are added and the mixture is stirred for one hour. 1.2 g (5.5 mmol) of methyl 5-bromo-2-thiophenecarboxylate and 60 mg (0.12 mmol) of the NiCl[0150] 2/DPPE complex are then added successively and the mixture is left stirring at room temperature for 12 hours. The reaction medium is poured into ice-water and extracted with ethyl ether and the organic phase is separated out after settling has taken place, dried over magnesium sulphate and evaporated. The residue obtained is chromatographed on a column of silica eluted with a mixture of hexane and dichloromethane (50/50% by volume). After evaporation of the solvents, 1.56 g (93%) of the expected methyl ester are collected, with a melting point of 94-5° C.
  • (b) 5-(3-tert-Butyl-4-methoxyphenyl)-2-thiophene-methanol [0151]
  • 1.5 g (5 mmol) of the above methyl ester and 50 ml of anhydrous THF are introduced into a three-necked flask under a stream of nitrogen. 280 mg (7.4 mmol) of lithium aluminium hydride are added and the mixture is refluxed for four hours. It is hydrolyzed with potassium sodium tartrate solution, the salt is filtered off and the filtrate is evaporated. The residue obtained is purified by chromatography on a column of silica eluted with a mixture of dichloromethane and hexane (70/30% by volume). After evaporation of the solvents, 1.26 g (92%) of the expected alcohol are recovered, in the form of a colourless oil. [0152]
  • (c) 5-(3-tert-Butyl-4-methoxyphenyl)-2-thiophene-carboxaldehyde [0153]
  • 7.15 g (19 mmol) of pyridinium dichromate and 350 ml of dichloromethane are introduced into a round-bottomed flask. A solution of 3.9 g (14 mmol) of 5-(3-tert-butyl-4-methoxyphenyl)-2-thiophenemethanol in 50 ml of dichloromethane is added dropwise, at 0° C., and the mixture is stirred at room temperature for two hours. The reaction medium is filtered through silica and, after evaporation, 3.26 g (84%) of the expected aldehyde are recovered, in the form of a brown oil. [0154]
  • (d) Ethyl 5-(3-tert-butyl-4-methoxyphenyl)-2-thiopheneacrylate [0155]
  • 200 mg (6.6 mmol) of sodium hydride (80% in oil) and 50 ml of dimethoxyethane are introduced into a three-necked flask under a stream of nitrogen and a solution of 1.3 ml (6.6 mmol) of triethyl phosphoacetate in 10 ml of dimethoxyethane is added dropwise. The mixture is stirred at room temperature for one hour and then, at 0° C., a solution of 1.5 g (5.5 mmol) of 5-(3-tert-butyl-4-methoxyphenyl)-2-thiophenecarboxaldehyde in 20 ml of dimethoxyethane is added dropwise. The reaction medium is stirred at room temperature for four hours and is then poured into water and extracted with ethyl ether, and the organic phase is separated out after settling has taken place, dried over magnesium sulphate and evaporated. The residue obtained is purified by chromatography on a column of silica eluted with a mixture of dichloromethane and hexane (30/70% by volume); 1.88 g (100%) of the expected ethyl ester are collected, in the form of a brown oil. [0156]
  • (e) 5-(3-tert-Butyl-4-methoxyphenyl)-2-thiophene-acrylic acid [0157]
  • 1.88 g (5.4 mmol) of the above ethyl ester, 20 ml of methanol and 1.88 g (47 mmol) of sodium hydroxide ae introduced into a round-bottomed flask and the mixture is refluxed for four hours. The reaction medium is evaporated to dryness, the residue is taken up in water and acidified to [0158] pH 1, and the solid is filtered off and dried. The solid obtained is recrystallized from ethanol, filtered off and dried. 1.09 g (63%) of 5-(3-tert-butyl-4-methoxyphenyl)-2-thiopheneacrylic acid are collected, with a melting point of 218-9° C.
    • EXAMPLE 2 5- (3-tert-Butyl-4-methoxyphenyl) -2-thiophene-propiolic acid
  • (a) 2′,2′-Dibromo-5-(3-tert-butyl-4-methoxyphenyl)-2-thiopheneethylene [0159]
  • 1.79 g (6.5 mmol) of 5-(3-tert-butyl-4-methoxyphenyl)-2-thiophenecarboxaldehyde prepared in Example 1(c) and 50 ml of dichloromethane are introduced into a round-bottomed flask. 4.32 g (13 mmol) of carbon tetrabromide, 3.41 g (13 mmol) of triphenylphosphine and 850 mg (13 mmol) of zinc powder are successively added and the mixture is stirred at room temperature for two hours. The reaction medium is evaporated and the residue obtained is purified by chromatography on a column of silica eluted with dichloromethane. 2.5 g (89%) of the expected product are collected. [0160]
  • (b) 5-(3-tert-Butyl-4-methoxyphenyl)-2-thiophene-acetylene [0161]
  • 2.48 g (5.7 mmol) of 2′,2′-dibromo-5-(3-tert-butyl-4-methoxyphenyl)-2-thiopheneethylene and 40 ml of THF are introduced into a three-necked flask under a stream of nitrogen. 5.1 ml (12.7 mmol) of n-butyllithium solution (2.5 M in hexane) are added dropwise, at −78° C., and the mixture is allowed to return to room temperature over one hour. The reaction medium is poured into water and extracted with ethyl ether, and the organic phase is separated out after settling has taken place, dried over magnesium sulphate and evaporated. The residue obtained is purified by chromatography on a column of silica eluted with heptane. 1.1 g (71%) of the expected acetylenic derivative are collected, in the form of a yellow oil. [0162]
  • (c) 5-(3-tert-Butyl-4-methoxyphenyl)-2-thiophene-propiolic acid [0163]
  • 1.1 g (4 mmol) of the above acetylenic derivative and 20 ml of THF are introduced into a three-necked flask under a stream of nitrogen. 1.95 ml (4.9 mmol) of n-butyllithium (2.5 M in hexane) are added dropwise, at −78° C., and the mixture is stirred for thirty minutes. A stream of CO[0164] 2 is passed through at −78° C. for fifteen minutes and the mixture is allowed to return to room temperature. The reaction medium is poured into aqueous ammonium chloride solution and extracted with ethyl ether, and the organic phase is separated out after settling has taken place, dried over magnesium sulphate and evaporated. The residue obtained is purified by chromatography on a column of silica eluted with dichloromethane. After evaporation of the solvents, 300 mg (23%) of 5-(3-tert-butyl-4-methoxyphenyl)-2-thiophenepropiolic acid are collected, with a melting point of 124-6° C.
    • EXAMPLE 3 2-(3-tert-Butyl-4-methoxyphenyl)-4-thiophene-acrylic acid
  • (a) 3-tert-Butyl-4-methoxyphenylboronic acid [0165]
  • 4 g (16.5 mmol) of 3-tert-butyl-4-methoxy-bromobenzene and 50 ml of THF are introduced into a three-necked flask under a stream of nitrogen. 7.9 ml (19.8 mmol) of n-butyllithium (2.5 M in hexane) are added dropwise at −78° C., the mixture is stirred for 15 minutes at this temperature, 5.6 ml (49.5 mmol) of trimethyl borate are added and the mixture is stirred for 2 hours. 20 ml of hydrochloric acid (1 N) are added at −50° C. and the mixture is allowed to return to room temperature. The reaction medium is extracted with ethyl ether and the organic phase is separated out after settling has taken place, dried over magnesium sulphate and evaporated. 3.79 g (100%) of the expected boronic acid are collected, which is used in its present state for the rest of the synthesis. [0166]
  • (b) Ethyl 2-(3-tert-butyl-4-methoxyphenyl)-4-thiophenecarboxylate [0167]
  • 260 mg (0.5 mmol) of tetrakis(triphenyl-phosphine)palladium(0), 50 ml of toluene and 2.59 g (10.9 m=ol) of ethyl 2-bromo-4-thiophenecarboxylate are introduced into a three-necked flask under a stream of nitrogen and the mixture is stirred at room temperature for 20 minutes. 3.7 g (16.5 mmol) of 3-tert-butyl-4-methoxyphenylboronic acid and 11 ml of aqueous sodium carbonate solution (2 N) are then added and the mixture is refluxed for 8 hours. The reaction medium is evaporated to dryness, the residue is taken up in water and ethyl ether and the organic phase is separated out after settling has taken place, dried over magnesium sulphate and evaporated. The residue is purified by chromatography on a column of silica eluted with a mixture of ethyl acetate and heptane (10/90% by volume). 3.53 g (69%) of ethyl 2-(3-tert-butyl-4-methoxyphenyl)-4-thiophenecarboxylate are obtained. [0168]
  • (c) 2-(3-tert-Butyl-4-methoxyphenyl)-4-thiophene-methanol [0169]
  • In a similar manner to Example 1(b), starting with 3.5 g (11 mmol) of ethyl 2-(3-tert-butyl-4-methoxyphenyl)-4-thiophenecarboxylate, 3.2 g (100%) of the expected alcohol are obtained in the form of a brown oil. [0170]
  • (d) 2-(3-tert-Butyl-4-methoxyphenyl)-4-thiophene-carboxaldehyde [0171]
  • In a similar manner to Example 1(c), starting with 3.2 g (11 mmol) of the above alcohol, 2.3 g (76%) of 2-(3-tert-butyl-4-methoxyphenyl)-4-thiophene-carboxaldehyde are obtained in the form of a brown oil. [0172]
  • (e) Ethyl 2-(3-tert-butyl-4-methoxyphenyl)-4-thiophene-acrylate [0173]
  • In a similar manner to Example 1(d), by reaction of 1.3 g (4.7 mmol) of 2-(3-tert-butyl-4-methoxyphenyl)-4-thiophenecarboxaldehyde with 1.28 g (5.7 mmol) of triethyl phosphonoacetate, 1.1 g (67%) of the expected ethyl ester are obtained, with a melting point of 119-20° C. [0174]
  • (f) 2-(3-tert-Butyl-4-methoxyphenyl)-4-thiophene-acrylic acid [0175]
  • In a similar manner to Example 1(e), starting with 1.1 g (3.2 mmol) of the above ethyl ester, 750 mg (74%) of 2-(3-tert-butyl-4-methoxyphenyl)-4-thiophene-acrylic acid are obtained, with a melting point of 197-8° C. [0176]
    • EXAMPLE 4 4- (3-tert-Butyl-4-methoxyphenyl) -2-thiophene-acrylic acid
  • (a) 4-(3-tert-Butyl-4-methoxyphenyl)-2-thiophene-carboxaldehyde [0177]
  • In a similar manner to Example 3(b), by reaction of 2.68 g (12.3 mmol) of 3-tert-butyl-4-methoxyphenylboronic acid with 1.55 g (2.12 mmol) of 4-bromo-2-thiophenecarboxaldehyde, 2.13 g (95%) of 4-(3-tert-butyl-4-methoxyphenyl)-2-thiophene-carboxaldehyde are obtained in the form of a yellow oil. [0178]
  • (b) Ethyl 4-(3-tert-butyl-4-methoxyphenyl)-2-thiopheneacrylate [0179]
  • In a similar manner to Example 1(d), by reaction of 1.2 g (4.3 mmol) of 4-(3-tert-butyl-4-methoxyphenyl)-2-thiophenecarboxaldehyde with 1.17 g (5.2 mmol) of triethyl phosphonoacetate, 1.55 g (100%) of the expected ethyl ester are obtained in the form of an oil. [0180]
  • (c) 4-(3-tert-Butyl-4-methoxyphenyl)-2-thiophene-acrylic acid [0181]
  • In a similar manner to Example 1(e), starting with 1.55 g (4.5 mmol) of the above ethyl ester, 1.14 g (88%) of 4- (3-tert-butyl-4-methoxyphenyl) -2-thiophene-acrylic acid are obtained, with a melting point of 206-7° C. [0182]
    • EXAMPLE 5 5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiopheneacrylic acid
  • (a) 3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthylboronic acid [0183]
  • In a similar tanner to Example 3(a), starting with 5 g (17.8 mmol) of 3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-bromonaphthalene, 4.22 g (100%) of boronic acid are obtained. [0184]
  • (b) 5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiophenecarboxaldehyde [0185]
  • In a similar manner to Example 3(b), by reaction of 4.2 g (17 mmol) of 3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthylboronic acid with 2.17 g (11.3 mmol) of 5-bromo-2-thiophenecarboxaldehyde, 2.1 g (60%) of the expected aldehyde are obtained, with a melting point of 130-5° C. [0186]
  • (c) Ethyl 5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiopheneacrylate [0187]
  • In a similar manner to Example 1(d), by reaction of 2 g (6.4 mmol) of 5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiophene-carboxaldehyde with 1.73 g (7.7 mmol) of triethyl phosphonoacetate, 2.02 g (82%) of the expected ethyl ester are obtained. [0188]
  • (e) 5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiopheneacrylic acid [0189]
  • In a similar manner to Example 1(e), starting with 2 g (5.2 =mmol) of the above ethyl ester, 1.79 g (96%) of 5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiopheneacrylic acid are obtained, with a melting point of 175-7° C. [0190]
    • EXAMPLE 6 4-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiopheneacrylic acid
  • (a) 4-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiophenecarboxaldehyde [0191]
  • In a similar manner to Example 3(b), by reaction of 4.2 g (17 mmol) of 3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthylboronic acid with 2.17 g (11.3 mmol) of 4-bromo-2-thiophenecarboxaldehyde, 2.75 g (78%) of the expected aldehyde are obtained, with a melting point of 144-6° C. [0192]
  • (b) Ethyl 4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiopheneacrylate [0193]
  • In a similar maser to Example 1(d), by reaction of 2.7 g (8.6 mmol) of 4-(3,5,5,8,8-penta-methyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiophene-carboxaldehyde with 2.1 ml (10.4 mmol) of triethyl phosphonoacetate, 2.76 g (84%) of the expected ethyl ester are obtained. [0194]
  • (c) 4-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiopheneacrylic acid [0195]
  • In a similar manner to Example 1(e), starting with 2.7 g (7.1 mmol) of the above ethyl ester, 2.5 g (98%) of 4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiopheneacrylic acid are obtained, with a melting point of 215-20° C. [0196]
    • EXAMPLE 7 4-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-thiopheneacrylic acid
  • (a) 5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthylboronic acid [0197]
  • In a similar manner to Example 3(a), starting with 5 g (18.7 mmol) of 5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-bromonaphthalene, 4.3 g (100%) of the expected boronic acid are obtained. [0198]
  • (b) 4-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-thiophenecarboxaldehyde [0199]
  • In a similar manner to Example 3(b), by reaction of 4.3 g (18.7 mmol) of 5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylboronic acid with 2.36 g (12.3 mmol) of 4-bromo-2-thiophenecarboxaldehyde, 2.3 g (63%) of the expected aldehyde derivative are obtained, with a melting point of 84-5° C. [0200]
  • (c) Ethyl 4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-thiopheneacrylate [0201]
  • In a similar manner to Example 1(d), by reaction of 2.28 g (8.3 mmol) of (5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-thiophene-carboxaldehyde with 2 ml (9.9 mmol) of triethyl phosphonoacetate, 810 mg (26%) of the expected ethyl ester are obtained, with a melting point of 82-4° C. [0202]
  • (d) 4-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-thiopheneacrylic acid [0203]
  • In a similar manner to Example 1(e), starting with 810 mg (2.2 mmol) of the above ethyl ester, 720 mg (96%) of 4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-thiopheneacrylic acid are obtained, with a melting point of 182-5° C. [0204]
    • EXAMPLE 8 5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiophenepropiolic acid
  • (a) 2′,2′-Dibromo-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiopheneethylene [0205]
  • In a similar manner to Example 2(a), starting with 3 g (9.6 mmol) of 5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiophene-carboxaldehyde, 4.56 g (100%) of 2′,2′-dibromo-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiopheneethylene are obtained. [0206]
  • (b) 5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiopheneacetylene [0207]
  • In a similar manner to Example 2(b), starting with 4.5 g (9.6 mmol) 2′,2′-dibromo-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiopheneethylene, 1.42 g (48%) of 5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiophene-acetylene are obtained. [0208]
  • (c) 5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiophenepropiolic acid [0209]
  • In a similar manner to Example 2(c), starting with 1.4 g (4.5 mmol) of the above acetylenic derivative, 800 mg (51%) of 5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiophenepropiolic acid are obtained, with a melting point of 138-40° C. [0210]
    • EXAMPLE 9 3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-phenylpropiolic acid
  • (a) 3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthylboronic acid [0211]
  • 100 g (0.356 mol) of 2-bromo-3,5,5,8,8-penta-methyl-5,6,7,8-tetrahydro-2-naphthalene and 1 litre of THF are introduced into a two-litre reactor under a stream of nitrogen, and the solution is cooled to −60° C. 157 ml (0.392 mol) of n-butyllithium (2.5 M in hexane) are added dropwise and the mixture is stirred for one hour. 121 ml (1.07 mol) of trimethyl borate are added dropwise at −70° C. and the mixture is stirred for one hour. 500 ml of hydrochloric acid (1 N) are added at −35° C. and the mixture is allowed to return to room temperature. The reaction medium is extracted with ethyl acetate and the organic phase is separated out after settling has taken place, washed twice with 500 ml of hydrochloric acid (1 N), dried over magnesium sulphate and evaporated. 83 g (95%) of the expected boronic acid are collected. [0212]
  • (b) 3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)benzaldehyde [0213]
  • 700 ml of DME, 2.4 g (2 mmol) of tetrakistriphenylphosphinepalladium(0) and 8.44 g (45.6 mmol) of 3-bromobenzaldehyde are introduced into a three-necked flask under a stream of nitrogen and the mixture is stirred for 10 minutes. A solution of 17 g (69.1 mmol) of 3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthylboronic acid in 25 ml of ethanol are then added, followed by 46 ml (91 mmol) of potassium carbonate solution (2 M) and the mixture is refluxed for four hours. The reaction medium is cooled and filtered and the solid is washed with bicarbonate solution and then with ethyl acetate. The solid obtained is recrystallized from ethanol and 7 g (50%) of the expected aldehyde are collected, with a melting point of 104-5° C. [0214]
  • (c) 2′,2′-Dibromo-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylethylene [0215]
  • In a similar manner to Example 2(a), starting with 2 g (6.5 mmol) of the above aldehyde, 1.96 g (65%) of the expected product are obtained in the form of a colourless oil. [0216]
  • (d) 3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacetylene [0217]
  • In a similar manner to Example 2(b), starting with 1.96 g (4.23 mmol) of 2′,2′-dibromo-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenyl-ethylene, 1.29 g (99%) of the expected acetylenic derivative are obtained in the form of a pale yellow oil. [0218]
  • (e) 3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylpropiolic acid [0219]
  • In a similar manner to Example 2(c), starting with 1.17 g (3.9 mmol) of the above acetylenic derivative, 900 mg (67%) of 3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylpropiolic acid are obtained, with a melting point of 180-1° C. [0220]
    • EXAMPLE 10 N-Methyl-4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-pyrroleacrylic acid
  • (a) 4-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-pyrrolecarboxaldehyde [0221]
  • In a similar manner to Example 3(b), by reaction of 5.9 g (25.6 mmol) of 5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylboronic acid with 3.7 g (21.3 mmol) of 4-bromo-2-pyrrolecarboxaldehyde, 1.3 g (21.6%) of the expected product are obtained, with a melting point of 211-2° C. [0222]
  • (b) N-Methyl-4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-pyrrolecarboxaldehyde [0223]
  • 1.3 g (4.6 mmol) of 4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-pyrrolecarboxaldehyde and 50 ml of THF are introduced into a three-necked flask under a stream of nitrogen. 300 mg (10 mmol) of sodium hydride (80% in oil) are added portionwise and the mixture is stirred until the evolution of gas has ceased. 640 μl (10 mmol) of iodomethane are then added and the mixture is stirred at room temperature for one hour. The reaction medium is poured into water and extracted with ethyl acetate, and the organic phase is separated out after settling has taken place, dried over magnesium sulphate and evaporated. The residue obtained is purified by chromatography on a column of silica eluted with a mixture of dichloromethane and heptane (70/30). After evaporation of the solvents, 600 mg (44%) of the expected product are collected. [0224]
  • (c) Ethyl N-methyl-4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-pyrroleacrylate [0225]
  • In a similar canner to Example 1(d), by reaction of 480 mg (1.3 mmol) of N-methyl-4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-pyrrolecarboxaldehyde with 400 μl (152 mmol) of triethyl phosphonoacetate, 350 mg of the expected ethyl ester are obtained in the form of an oil. [0226]
  • (d) N-Methyl-4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-pyrroleacrylic acid [0227]
  • In a similar manner to Example 1(e), starting with 350 mg (0.94 mmol) of the above ethyl ester, 170 mg (23%) of N-methyl-4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-pyrroleacrylic acid are obtained, with a melting point of 185-6° C. [0228]
    • EXAMPLE 11 3-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid
  • (a) 3-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylcarboxaldehyde [0229]
  • In a similar manner to Example 3(b), by reaction of 6.43 g (27.7 mmol) of 5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylboronic acid with 2.7 ml (23.1 mmol) of 4-bromobenzaldehyde, 2.05 g (24%) of 3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-phenylcarboxaldehyde are obtained in the form of a pale yellow oil. [0230]
  • (b) Ethyl 3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylate [0231]
  • In a similar manner to Example 1(d), by reaction of 800 mg (2.7 mmol) of 3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylcarboxaldehyde with 650 ml (3.3 mmol) of triethyl phosphonoacetate, 900 mg (91%) of the expected ethyl ester are obtained in the form of a colourless oil. [0232]
  • (c) 3-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid [0233]
  • In a similar manner to Example 1a), starting with 1.22 g (2.7 mmol) of the above ethyl ester, 380 mg (41%) of 3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid are obtained, with a melting point of 210-1° C. [0234]
    • EXAMPLE 12 N-Methyl-4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-pyrroleacrylic acid
  • (a) N-Methyl-4-bromo-2-pyrrolecarboxaldehyde [0235]
  • In a similar manner to Example 10(b), by reaction of 4 g (23 mmol) of 4-bromo-2-pyrrolecarboxaldehyde with 1.7 ml (27.6 mmol) of iodomethane, 2.3 g (50%) of the expected product are obtained, with a melting point of 123-4° C. [0236]
  • (b) N-Methyl-4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-pyrrolecarboxaldehyde [0237]
  • In a similar manner to Example 3(b), by reaction of 3 g (12.1 mmol) of 3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthylboronic acid with 1.9 g (10.1 mmol) of N-methyl-4-bromo-2-pyrrole-carboxaldehyde, 1.85 g (59%) of the expected product are obtained in the form of a pale yellow oil. [0238]
  • (c) Ethyl N-methyl-4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-pyrroleacrylate [0239]
  • In a similar manner to Example 1(d), by reaction of 1.85 g (6 mmol) of N-methyl-4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-pyrrole-carboxaldehyde with 1.4 ml (7.2 mmol) of triethyl phosphonoacetate, 2.1 g (92%) of the expected ethyl ester are obtained in the form of an orange-coloured oil. [0240]
  • (d) N-Methyl-4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-pyrroleacrylic acid [0241]
  • In a similar manner to Example 1(e), starting with 2 g (5.3 mmol) of the above ethyl ester, 730 mg (39.5%) of N-methyl-4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-pyrroleacrylic acid are obtained, with a melting point of 185-6° C. [0242]
    • EXAMPLE 13 4-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-pyrroleacrylic acid
  • (a) 4-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-pyrrolecarboxaldehyde [0243]
  • In a similar manner to Example 3(b), by reaction of 2.47 g (10 mmol) of 3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthylboronic acid with 1.5 g (8.4 mmol) of 4-bromo-2-pyrrolecarboxaldehyde, 950 mg (38.5%) of the expected aldehyde are obtained, with a melting point of 128-9° C. [0244]
  • (b) Ethyl 4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-pyrroleacrylate [0245]
  • In a similar manner to Example 1(d), by reaction of 500 mg (1.7 mmol) of 4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-pyrrolecarboxaldehyde with 400 μl (2 mmol) of triethyl phosphonoacetate, 570 mg (92%) of the expected ethyl ester are obtained. [0246]
  • (c) 4-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-pyrroleacrylic acid [0247]
  • In a similar manner to Example 1(e), starting with 570 mg (1.9 mmol) of ethyl 4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-pyrroleacrylate, 240 mg (37%) of 4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-pyrroleacrylic acid are obtained, with a melting point of 245-6° C. [0248]
    • EXAMPLE 14 3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid
  • In a similar manner to Example 9(b), by reaction of 73.4 g (0.30 mol) of 3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthylboronic acid with 44.7 g (0.20 mol) of 4-bromophenylacrylic acid, and after recrystallization from ethanol, 48 g (61%) of 3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid are obtained, with a melting point of 207-8° C. [0249]
    • EXAMPLE 15 3-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylpropiolic acid
  • (a) 2′,2′-Dibromo-3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylethylene [0250]
  • In a similar manner to Example 2(a), starting with 2.05 g (7 mmol) of 3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)benzaldehyde [prepared in Example 11(a)], 1.07 g (35%) of the expected product are obtained in the form of an oil. [0251]
  • (b) 3-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylpropiolic acid [0252]
  • 900 mg (2 mmol) of 2′,2′-dibromo-3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-napthyl)phenyl-etheylene and 40 ml of THF are introduced into a three-necked flask under a stream of nitrogen. 2.2 ml (5.2 mmol) of n-butyllithium solution (2.5 M in hexane) are added dropwise at −50° C. and the mixture is allowed to return to room temperature. CO[0253] 2 is introduced at 0° C. for 20 minutes and the mixture is stirred at room temperature for one hour. The reaction medium is poured into saturated ammonium chloride solution and adjusted to pH 1 with hydrochloric acid, the mixture is extracted with ethyl acetate and the organic phase is separated out after settling has taken place, dried over magnesium sulphate and evaporated. The residue obtained is purified by chromatography on a column of silica eluted with a mixture of dichloromethane and methanol (95/5). After evaporation of the solvents, 80 mg (12%) of 3-(5,6,7,8-tetrahydro-5,5,8,8-tetra-methyl-2-naphthyl)phenylpropiolic acid are collected, with a melting point of 164-5° C.
    • EXAMPLE 16 2-Methoxy-5-(3,5,5.8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl) phenylacrylic acid
  • (a) 2-Hydroxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetra-hydro-2-naphthyl)benzaldehyde [0254]
  • In a similar manner to Example 9(b), by reaction of 15 g (61 mmol) of 3,5,5,8,3-pentamethyl-5,6,7,8-tetrahydro-2-naphthylboronic acid with 8.16 g (41 mmol) of 5-bromo-2-hydroxybenzaldehyde, 11.7 g (89%) of 2-hydroxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)benzaldehyde are obtained, with a melting point of 138-9° C. [0255]
  • (b) 2-Methoxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetra-hydro-2-naphthyl)benzaldehyde [0256]
  • In a similar manner to Example 10(b), by reaction of 2 g (6.2 mmol) of 2-hydroxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)benzaldehyde with 425 μl (6.8 mmol) of iodomethane, 1.68 g (88%) of the expected product are obtained. [0257]
  • (c) Ethyl 2-methoxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylate [0258]
  • In a similar manner to Example 1(d), by reaction of 1.65 g (5 mmol) of 2-methoxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)benzaldehyde with 1.68 g (7.5 mmol) of triethyl phosphonoacetate, 1.7 g (83%) of the expected ethyl ester are obtained in the form of an oil. [0259]
  • (d) 2-Methoxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetra-hydro-2-naphthyl)phenylacrylic acid [0260]
  • In a similar manner to Example 1(e), starting with 1.6 g (3.9 mmol) of the above ethyl ester, 1.4 g (93%) of 2-methoxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid are obtained, with a melting point of 181-2° C. [0261]
    • EXAMPLE 17 2-Propyloxy-5-(3,5,5,8,9-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-phenylacrylic acid
  • (a) 2-Propyloxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)benzaldehyde [0262]
  • In a similar manner to Example 10(b), by reaction of 2 g (6.2 mmol) of 2-hydroxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)benzaldehyde [prepared in Example 16(a)] with 670 μl (6.8 mmol) of 1-iodopropane, 2.2 g (88%) of the expected product are obtained in the form of a colourless oil. [0263]
  • (b) Ethyl 2-propyloxy-5- (3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylate [0264]
  • In a similar manner to Example 1(d), by reaction of 2.18 g (6 mmol) of 2-propyloxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)benzaldehyde with 2.03 g (9 mmol) of triethyl phosphonoacetate, 2.13 g (82%) of the expected ethyl ester are obtained in the form form of a yellow oil. [0265]
  • (c) 2-Propyloxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid [0266]
  • In a similar manner to Example 1(e), starting with 2.1 g (4.8 mmol) of the above ethyl ester, 1.68 g (86%) of 2-propyloxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid are obtained, with a melting point of 125-6° C. [0267]
    • EXAMPLE 18 2-Heptyloxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid
  • (a) 2-Heptyloxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)benzaldehyde [0268]
  • In a similar manner to Example 10(b), by reaction of 2 g (9.3 mmol) of 2-hydroxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)benzaldehyde [prepared in Example 16(a)] with 1.1 ml (6.8 mmol) of 1-bromoheptane, 1.88 g (72%) of the expected product are obtained in the form of a yellow oil. [0269]
  • (b) Ethyl 2-heptyloxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylate [0270]
  • In a similar manner to Example 1(d), by reaction of 1.78 g (4.2 mmol) of 2-heptyloxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)benzaldehyde with 1.44 g (6.3 mmol) of triethyl phosphonoacetate, 1.89 g (90%) of the expected ethyl ester are obtained in the form of a yellow oil. [0271]
  • (c) 2-Heptyloxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid [0272]
  • In a similar manner to Example 1(e), starting with 1.89 g (3.9 mmol) of the above ethyl ester, 1.2 g (67%) of 2-heptyloxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid are obtained, with a melting point of 137-8° C. [0273]
    • EXAMPLE 19 2-Methoxymethoxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid
  • (a) 2-Methoxymethoxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)benzaldehyde [0274]
  • In a similar manner to Example 10(b), by reaction of 3 g (9.3 mmol) of 2-hydroxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)benzaldehyde [prepared in Example 16(a)] with 777 μl (10.2 mmol) of methoxymethyl chloride, 3.5 g (100%) of the expected product are obtained in the form of an oil. [0275]
  • (b) Ethyl 2-methoxymethoxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylate [0276]
  • In a similar manner to Example 1(d), by reaction of 3.4 g (9.3 mmol) of 2-methoxymethoxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-benzaldehyde with 4.16 g (18.6 mmol) of triethyl phosphonoacetate, 3.5 g (86%) of the expected ethyl ester are obtained, with a melting point of 100-1° C. [0277]
  • (c) 2-Methoxymethoxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid [0278]
  • In a similar manger to Example 1(e), starting with 1.5 g (3.4 mmol) of the above ethyl ester, 1.2 g (86%) of 2-methoxymethoxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid are obtained, with a melting point of 191-2° C. [0279]
    • EXAMPLE 20 2-Hydroxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid
  • (a) Methyl 2-hydroxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-phenylacrylate [0280]
  • 1.9 g (4.35 mmol) of 2-methoxymethoxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid, 20 ml of methanol and 30 ml of THF are introduced into a round-bottomed flask. 2.8 ml of concentrated sulphuric acid are added and the mixture is stirred at room temperature for 12 hours. The reaction medium is poured into water and extracted with ethyl ether, and the organic phase is separated out after settling has taken place, washed with water, dried over magnesium sulphate and evaporated. 1.63 g (95%) of methyl 2-hydroxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylate are collected. [0281]
  • (b) 2-Hydroxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetra-hydro-2-naphthyl)phenylacrylic acid [0282]
  • In a similar manner to Example 1(e), starting with 1.63 g (4.25 mmol) of the above ethyl ester, 1.3 g (85%) of 2-hydroxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid are obtained, with a melting point of 204-5° C. [0283]
    • EXAMPLE 21 3-(3-Methoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid
  • (a) 3-Bromo-2-methoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene [0284]
  • 7 g (24.7 mmol) of 3-bromo-2-hydroxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene and 40 ml of DMF are introduced into a three-necked flask under a stream of nitrogren. 890 mg (29.6 mmol) of sodium hydride (80% in oil) are added portionwise and the mixture is stirred until the evolution of gas has ceased. 1.7 ml (27 mmol) of iodomethane are then added and the mixture is stirred at room temperature for one hour. The reaction medium is poured into water and extracted with ethyl ether, and the organic phase is separated out after settling has taken place, dried over magnesium sulphate and evaporated. 7.3 g (99%) of the expected product are collected in the form of an oil which crystallizes slowly. Melting point 77-8° C. [0285]
  • (b) 2-Methoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-naphthylboronic acid [0286]
  • In a similar manner to Example 3(a), starting with 6.7 g (22.5 mmol) of 3-bromo-2-methoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene, 4.54 g (77%) of the expected boronic acid are obtained, with a melting point of 151-2° C. [0287]
  • (c) 3-(3-Methoxy-5,6,7,8-tetrahydro-5,5,8,8-tetra-methyl-2-naphthyl)phenylacrylic acid [0288]
  • In a similar manner to Example 9(b), by reaction of 2.62 g (10 mmol) of 2-methoxy-5,6,7,8-tetramethylnaphthylboronic acid with 1.51 g (6.7 mmol) of 3-bromophenylacrylic acid, 1.1 g (45%) of 3-(3-methoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid are obtained, with a melting point of 187-8° C. [0289]
    • EXAMPLE 22 3-(3-Propyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid
  • (a) 3-Bromo-2-propyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene [0290]
  • In a similar manner to Example 21(a), by reaction of 7 g (24.7 mmol) of 3-bromo-2-hydroxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene with 2.45 ml (27 mmol) of 1-bromopropane, 8.1 g (100%) of 3-bromo-2-propyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene are obtained in the form of an orange-coloured oil. [0291]
  • (b) 2-Propyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetra-methylnaphthylboronic acid [0292]
  • In a similar manner to Example 3(a), by reaction of 8 g (24.6 mmol) of 3-bromo-2-propyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene, 5.7 g (80%) of the expected-boronic acid are obtained, with a melting point of 138-9° C. [0293]
  • (c) 3-(3-Propyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetra-methyl-2-naphthyl)phenylacrylic acid [0294]
  • In a similar manner to Example 9(b), by reaction of 5 g (17.2 mmol) of 2-propyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthylboronic acid with 2.6 g (11.5 mmol) of 3-bromophenylacrylic acid, 1.66 g (35%) of 3-(3-propyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid are obtained, with a melting point of 172-3° C. [0295]
    • EXAMPLE 23 3-(3-Heptyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid
  • (a) 3-Bromo-2-heptyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene [0296]
  • In a similar manner to Example 21(a), by reaction of 7 g (24.7 mmol) of 3-bromo-2-hydroxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene with 4.24 ml (27 mmol) of 1-bromoheptane, 10 g (100%) of 3-bromo-2-heptyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene are obtained in the form of a brown oil. [0297]
  • (b) 2-Heptyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetra-methylnaphthylboronic acid [0298]
  • In a similar manner to Example 3(a), starting with 10 g (26.2 mmol) of 3-bromo-2-heptyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene, 6.1 g (67%) of the expected boronic acid are obtained, with a melting point of 102-3° C. [0299]
  • (c) 3-(3-Heptyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetra-methyl-2-naphthyl)phenylacrylic acid [0300]
  • In a similar manner to Example 9(b), by reaction of 5 g (14.4 mmol) of 2-haptyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthylboronic acid with 2.52 g (11.1 mmol) of 3-bromophenylacrylic acid, 2.7 g (54%) of 3-(3-heptyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid are obtained, with a melting point of 112-3° C. [0301]
    • EXAMPLE 24 3-(3-Methoxymethoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid
  • (a) 3-Bromo-2-methoxymethoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalane [0302]
  • In a similar manner to Example 21(a), by reaction of 7 g (24.7 mmol) of 3-bromo-2-hydroxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene with 2.05 ml (27 m=ol) of methoxymethyl chloride, 8.1 g (100%) of 3-bromo-2-methoxymethoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene are obtained in the form of a light-brown oil. [0303]
  • (b) 2-Methoxymethoxy-5,6,7,8-tetrahydro-5,5,8,8-tetra-methylnaphthylboronic acid [0304]
  • In a similar manner to Example 3(a), starting with 8 g (24.4 mmol) of 3-bromo-2-methoxymethoxy-5,6,7,8-tetrahydro-5,5,8,8-tatrametbylnaphthalene, 5.5 g (77%) of the expected boronic acid are obtained, with a melting point of 133-4° C. [0305]
  • (c) 3-(3-Methoxymethoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid [0306]
  • In a similar manner to Example 9(b), by reaction of 5.3 g (18.1 mmol) of 2-methoxymethoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthylboronic acid with 3.16 g (14 mmol) of 3-bromophenylacrylic acid, 4.39 g (80%) of 3-(3-methoxymethoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid are obtained, with a melting point of 156-7° C. [0307]
    • EXAMPLE 25 3- (3-Hydroxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid
  • (a) Methyl 3-(3-hydroxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylate [0308]
  • 2 g (5 mmol) of 3-(3-methoxymethoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid, 10 ml of methanol and 10 ml of THF are introduced into a round-bottomed flask. 2.8 ml of concentrated sulphuric acid are added and the mixture is stirred at room temperature for &é hours. The reaction medium is poured into water and extracted with ethyl ether, and the organic phase is separated out after settling has taken place, washed with water, dried over magnesium sulphate and evaporated. 1.80 g (98%) of the expected methyl ester are collected, with a melting point of 182-3° C. [0309]
  • (b) 3-(3-Hydroxy-5,6,7,8-tetrahydro-5,5,8,8-tetra-methyl-2-naphthyl)phenylacrylic acid [0310]
  • In a similar manner to Example 1(e), starting with 1.5 g (4.1 mmol) of the above methyl ester, 1.3 g (90%) of 3-(3-hydroxy-5,6,7,8-tetrahydro-5,5,8,8-tetra-methyl-2-naphthyl)phenylacrylic acid are obtained, with a melting point of 244-5° C. [0311]
    • EXAMPLE 26 3-(4,4,7-Trimethylthiochroman-6-yl)phenyl-acrylic acid
  • (a) 1-Methyl-3-(3-methylbut-2-enyl)sulphanylbenzene [0312]
  • 5 g (40 mmol) of 3-methylthiophenol, 5.6 g (40 mmol) of potassium carbonate and 50 ml of DMF are introduced into a three-necked flask. 7.2 g (48 mmol) of 3-methyl-2-butene bromide are added and the mixture is stirred at room temperature for four hours. The reaction medium is poured into water and extracted with ethyl ether, and the organic phase is separated out after settling has taken place, dried over magnesium sulphate and evaporated. 7.8 g (100%) of the expected product are collected in the form of a yellow oil. [0313]
  • (b) 4,4,7-Trimethylthiochroman [0314]
  • 7 g (36.4 mmol) of 1-methyl-3-(3-methylbut-2-enyl)sulphanylbenzene and 50 ml of toluene are introduced into a round-bottomed flask and 10.4 g (54.6 mol) of para-toluenesulphonic acid are added. The mixture is refluxed for four hours. The reaction medium is evaporated to dryness, the residue is taken up in water and ethyl ether and the organic phase is separated out after settling has taken place, dried over magnesium sulphate and evaporated. 6.8 g (97%) of the thiochroman are collected in the form of a brown oil. [0315]
  • (c) 6-Bromo-4,4,7-trimethylthiochroman [0316]
  • 6.2 g (32.2 mol) of 4,4,7-trimethylthio-chroman, 40 ml of dichloromethane and 90 mg of iron powder are introduced into a three-necked flask. 1.65 ml (32.2 mmol) of bromine are added and the mixture is stirred at room temperature for two hours. The reaction medium is poured into sodium bicarbonate solution and extracted with dichloromethane, and the organic phase is separated out-after settling has taken place, dried over magnesium sulphate and evaporated. The residue obtained is purified by chromatography on a column of silica eluted with heptane. 5.9 g (67%) of the bromo derivative are collected in the form of a pale yellow oil. [0317]
  • (d) 4,4,7-Trimethylthiochromanylboronic acid [0318]
  • In a similar manner to Example 3(a), starting with 5.8 g (21.4 mmol) of 6-bromo-4,4,7-trimethylthio-chroman, 3.88 g (76%) of the expected boronic acid are obtained, with a melting point of 252-3° C. [0319]
  • (e) 3-(4,4,7-Trimethylthiochroman-6-yl)phenylacrylic acid [0320]
  • In a similar manner to Example 9(b), by reaction of 1.5 g (6.3 mmol) of 4,4,7-trimethylthio-chromanylboronic acid with 1.2 g (5.3 mmol) of 3-bromophenylacrylic acid, 1.1 g (99%) of 3-(4,4,7-trimethylthiochroman-6-yl)phenylacrylic acid are obtained, with a melting point of 102-3° C. [0321]
    • EXAMPLE 27 N-Ethyl-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-phenylacrylamide
  • (a) 3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacryloyl chloride [0322]
  • 3.5 g (10 mmol) of 3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid and 50 ml of dichloromethane are introduced into a round-bottomed flask and 2 ml (10 mmol) of dicylcohexylamine are added. The mixture is stirred at room temperature for 10 minutes and 729 μl (10 mmol) of thionyl chloride are then introduced with stirring for 15 minutes. The reaction medium is evaporated to dryness, the residue is taken up in ethyl ether, the dicyclohexylamine salt is filtered off and the filtrate is evaporated. 3.7 g (100%) of the crude acid chloride are collected, which will be used in its current state for the rest of the synthesis. [0323]
  • (b) N-Ethyl-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetra-hydro-2-naphthyl)phenylacrylamide [0324]
  • 20 ml of THF are introduced into a round-bottomed flask and 2.8 ml (35 mmol) of ethylamine solution (70%) are added. A solution of 1.2 g (3.2 mmol) of 3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetra-hydro-2-naphthyl)phenylacryloyl chloride in 40 ml of THF is added dropwise and the mixture is stirred at room temperature for one hour. The reaction medium is acidified with hydrochloric acid and extracted with ethyl ether, and the organic phase is separated out after settling has taken place, dried over magnesium sulphate and evaporated. The residue obtained is purified by chromatography on a column of silica eluted with dichloromethane. After evaporation of the solvents, 817 mg (68%) of N-ethyl-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-phenylacrylamide are collected, with a melting point of 158-9° C. [0325]
    • EXAMPLE 28 N-(4-Hydroxyphenyl)-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-phenylacrylamide
  • In a similar manner to Example 27(a), by reaction of 1.2 g (3.2 mmol) of 3-(3,5,5,8,8-penta-methyl-5,6,7,6- tetrahydro-2-naphthyl)phenylacryloyl chloride with 349 mg (3.2 mmol) of 4-hydroxyaniline, 810 mg of (57%) of N-(4-hydroxyphenyl)-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenyl-acrylamide are obtained, with a melting point of 240-1° C. [0326]
    • EXAMPLE 29 3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid morpholide
  • In a similar manner to Example 27(a), by reaction of 1.3 g (3.4 mmol) of 3-(3,5,5,8,8-penta-methyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacryloyl chloride with 620 μl of (7.12 mmol) of morpholine, 1.25 g (88%) of 3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid morpholide are obtained, with a melting point of 158-9° C. [0327]
    • EXAMPLE 30 Ethyl 3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl) -phenylacrylate
  • In a similar tanner to Example 1(d), by reaction of 5 g (16.3 mmol) of 3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)benzaldehyde with 4.79 g (21.2 mmol) of triethyl phosphonoacetate, 5 g (81%) of ethyl 3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylate are obtained, with a melting point of 70-2° C. [0328]
    • EXAMPLE 31 3-[3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetra-hydro-2-naphthyl)phenyl]but-2-enoic acid
  • (a) 3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)acetophenone [0329]
  • In a similar manner to Example 9(b), by reaction of 5 g (20.3 mmol) of 3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthylboronic acid with 2.7 g (13.5 mmol) of 3-bromoacetophenone, 4.3 g (90%) of the expected product are obtained, with a melting point of 89-90° C. [0330]
  • (b) Ethyl 3-[3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetra-hydro-2-naphthyl)phenyl]but-2-enoate [0331]
  • In a similar manner to Example 1(d), by reaction of 3.7 g (11.5 mmol) of 3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)acetophenone with 3.9 g (17.3 mmol) of triethyl phosphonoacetate, 2.67 g (60%) of the expected ethyl ester are obtained in the form of a yellow oil. [0332]
  • (c) 3-[3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenyl]but-2-enoic acid [0333]
  • In a similar manner to Example 1(e), starting with 2.5 g (6.4 mmol) of the above ethyl ester, 1.63 g (70%) of 3-[3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenyl]but-2-enoic acid are obtained, with a melting point of 166-7° C. [0334]
    • EXAMPLE 32
  • Various solid formulations based on compounds according to the invention are illustrated in this example. [0335]
    A- ORAL ROUTE
    (a) 0.2 g tablet
    Compoud of Example 1 0.001 g
    Starch 0.114 g
    Dicalcium phosphate 0.020 g
    Silica 0.020 g
    Lactose 0.030 g
    Talc 0.010 g
    Magnesium stearate 0.005 g
    (b) Drinkable suspension in 5 ml ampoules
    Compound of Example 3 0.001 g
    Glycerol 0.500 g
    70% Sorbitol 0.500 g
    Sodium saccharinate 0.010 g
    Methyl para-hydroxybenzoate 0.040 g
    Flavouring qs
    Purified water qs 5 ml
    (c) 0.8 g tablet
    Compound of Example 5 0.500 g
    Pregelatinized starch 0.100 g
    Microcrystalline cellulose 0.115 g
    Lactose 0.075 g
    Magnesium stearate 0.010 g
    (d) Drinkable suspension in 10 ml ampoules
    Compound of Example 2 0.050 g
    Glycerol 1.000 g
    70% Sorbitol 1.000 g
    Sodium saccharinate 0.010 g
    Methyl para-hydroxybenzoate 0.080 g
    Flavouring qs
    Purified water qs 10 ml
    TOPICAL ROUTE
    (a) Ointment
    Compound of Example 21 0.020 g
    Isopropyl myristate 81.700 g
    Liquid petroleum jelly 9.100 g
    Silica (“Aerosil 200” sold by 9.180 g
    Degussa)
    (b) Ointment
    Compound of Example 9 0.300 g
    White petroleum jelly codex qs 100 g
    (c) Nonionic water-in-oil cream
    Compound of Example 7 0.100 g
    Mixture of emulsifying lanolin 39.900 g
    alcohols, waxes and oils (“Anhydrous
    Eucerin” sold by BDF)
    Methyl para-hydroxybenzoate 0.075 g
    Propyl para-hydroxybenzoate 0.075 g
    Sterile demineralized water qs 100 g
    (d) Lotion
    Compound of Example 30 0.100 g
    Polyethylene glycol (PEG 400) 69.900 g
    95% Ethanol 30.000 g
    (e) Hydrophobic ointment
    Compound of Example 25 0.300 g
    Isopropyl myristate 36.400 g
    Silicone oil (“Rhodorsil 47 V 300” 36.400 g
    sold by Rhône-Poulenc)
    Beeswax 13.600 g
    Silicone (“Abil 300,000 cst” 100 g
    sold by Goldschmidt) qs
    (f) Nonionic oil-in-water cream
    Compound of Example 14 0.500 g
    Cetyl alcohol 4.000 g
    Glyceryl monostearate 2.500 g
    PEG 50 stearate 2.500 g
    Karite butter 9.200 g
    Propylene glycol 2.000 g
    Methyl para-hydroxybenzoate 0.075 g
    Propyl para-hydroxybenzoate 0.075 g
    Sterile demineralized water qs 100 g

Claims (11)

1. Bicyclic aromatic compounds, characterized in that they correspond to the general formula (I) below:
Figure US20030135053A1-20030717-C00007
in which:
R1 represents
(i) the —CH3 radical
(ii) the radical —CH2OR5
(iii) the radical —COR6
R5 and R6 having the meaning given below
Ar represents a radical chosen from the radicals of formulae (a)-(e) below:
Figure US20030135053A1-20030717-C00008
R5 and R7 having the meaning given below,
X represents
Figure US20030135053A1-20030717-C00009
R8 and R9 having the meanings given below
R2 and R3, which may be identical or different, represent
(i) a hydrogen atom,
(ii) an alkyl radical having at least 3 carbon atoms, among which the carbon attached to the phenyl radical is substituted with at least two carbon atoms,
(iii) a radical —OR5,
(iv) a radical —SR5,
R5 having the meaning given below, it being understood that R2 and R3, taken together, may form with the adjacent aromatic ring a 5- or 6-membered ring optionally substituted with methyl groups and/or optionally interrupted by an oxygen or sulphur atom,
and it being understood that R2 and R3 cannot at the same time have the meanings (i), (iii) and (iv) mentioned above,
R4 and R7, which may be identical or different, represent a hydrogen atom, a halogen atom, a linear or branched alkyl radical having from 1 to 20 carbon atoms or a radical —OR5,
R5 represents a hydrogen atom, a lower alkyl radical or a radical —COR10
R10 having the meaning given below,
R6 represents:
(a) a hydrogen atom
(b) a lower alkyl radical
(c) a radical of formula:
Figure US20030135053A1-20030717-C00010
R′ and R″ having the meaning given below,
(d) a radical —OR11
R11 having the meaning given below,
R8 and R9, which may be identical or different, represent a hydrogen atom or a lower alkyl radical,
R10 represents a lower alkyl radical,
R11 represents a hydrogen atom, a linear or branched alkyl radical having from 1 to 20 carbon atoms, an alkenyl radical, a mono- or polyhydroxyalkyl radical, an optionally substituted aryl or aralkyl radical, a sugar residue or an amino acid or peptide residue,
R′ and R″, which may be identical or different, represent a hydrogen atom, a lower alkyl radical, a mono- or polyhydroxyalkyl radical, an optionally substituted aryl radical or an amino acid or sugar residue, or alternatively, taken together form a heterocycle,
as well as the salts thereof and the optical and geometrical isomers thereof.
2. Compounds according to claim 1, characterized in that they are in the form of salts of an alkali metal or alkaline-earth metal, or alternatively of zinc or of an organic amine.
3. Compounds according to claim 1, characterized in that they are taken, alone or as mixtures, from the group consisting of:
5-(3-tert-Butyl-4-methoxyphenyl)-2-thiophene-acrylic acid,
5-(3-tert-Butyl-4-methoxyphenyl)-2-thiophene-propiolic acid,
2-(3-tert-Butyl-4-methoxyphenyl)-4-thiophene-acrylic acid,
4-(3-tert-Butyl-4-methoxyphenyl)-2-thiophene-acrylic acid,
5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiopheneacrylic acid,
4-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiophenepropiolic acid,
4-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-thiopheneacrylic acid,
5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiophenepropiolic acid,
3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylpropiolic acid,
N-Methyl-4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-pyrroleacrylic acid,
3-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid,
N-Methyl-4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-pyrroleacrylic acid,
4-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-pyrroleacrylic acid,
3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
3-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylpropiolic acid,
2-Methoxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
2-Propyloxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
2-Heptyloxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
2-Methoxymethoxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
2-Hydroxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
3-(3-Methoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid,
3-(3-Propyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid,
3-(3-Heptyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl) phenylacrylic acid,
3-(3-Methoxymethoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid,
3-(3-Hydroxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid,
3-(4,4,7-Trimethylthiochroman-6-yl)-phenylacrylic acid,
N-Ethyl-3-(3,5,5,8,8-pentamethyl-5,6,7, tetrahydro-2-naphthyl)phenylacrylamide,
N-(4-Hydroxyphenyl)-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylamide,
3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid morpholide,
Ethyl 3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylate,
3-[3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenyl]but-2-enoic acid,
4-Methoxymethoxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
4-Hydroxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
4-Methoxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
4-Propyloxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
4-Heptyloxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-phenyl]acrolein,
3-[3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenyl]prop-2-en-1-ol,
cis-3-[3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenyl]but-2-enoic acid,
cis-3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-3-pyridineacrylic acid,
3-(3-Butyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid,
6-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-pyridineacrylic acid.
4. Compounds according to claim 1, characterized in that they have at least one, and preferably all, of the following characteristics:
R1 represents the radical —COR5
Ar represents the radicals of formula (a) or (d)
X represents the radical
Figure US20030135053A1-20030717-C00011
R2 and R3, taken together, form, with the adjacent aromatic ring, a 5- or 6-membered ring optionally substituted with methyl groups and/or optionally interrupted by an oxygen or sulphur atom.
5. Compounds according to any one of the preceding claims, for use as a medicinal product.
6. Compounds according to claim 5, for use as a medicinal product intended for the treatment of dermatological complaints associated with a keratinization disorder which has a bearing on differentiation and on proliferation, in particular for treating common acne, comedones, polymorphonuclear leukocytes, rosacea, nodulocystic acne, acne conglobata, senile acne and secondary acnes such as solar, medication-related or profession-related acne; for treating other types of keratinization disorder, in particular ichthyosis, ichthyosiform states, Darier's disease, palmoplantar keratoderma, leucoplasias and leucoplasiform states, and cutaneous or mucous (buccal) lichen; for treating other dermatological complaints associated with a keratinization disorder with an inflammatory and/or immunoallergic component and, in particular, all forms of psoriasis, whether it is cutaneous, mucous or ungual psoriasis and even psoriatic rheumatism, or alternatively cutaneous atopy, such as eczema or respiratory atopy or alternatively gingival hypertrophy; the compounds may also be used for some inflammatory complaints which show no keratinization disorder; for treating all dermal or epidermal hyperproliferations, whether benign or malignant and whether they are of viral origin or otherwise, such as common warts, flat warts and verruciform epidermodysplasia, it being possible for the oral or florid papillomatoses and the hyperproliferations to be induced by ultraviolet radiation, in particular in the case of basocellular and spinocellular epithelioma; for treating other dermatological disorders such as bullosis and collagen diseases; for treating certain ophthalmological disorders, in particular corneopathies; for repairing or combating ageing of the skin, whether this is light-induced or chronological ageing, or for reducing actinic keratoses and pigmentations, or any pathologies associated with chronological or actinic ageing; for preventing or curing the stigmata of epidermal and/or dermal atrophy induced by local or systemic corticosteroids, or any other form of cutaneous atrophy; for preventing or treating cicatrization disorders or for preventing or repairing vibices; for favouring cicatrization, for combating disorders of sebaceous functioning such as the hyperseborrhoea of acne or simple seborrhoea; in the treatment or prevention of cancerous or precancerous states, more particularly promyelocytary leukemia; in the treatment of inflammatory complaints such as arthritis; in the treatment of any general or skin complaint of viral origin; in the prevention or treatment of alopecia; in the treatment of dermatological complaints having an immuological component; in the treatment of complaints of the cardiovascular system such as arteriosclerosis or hypertension, as well as insulin-independent diabetes, in the treatment of skin disorders caused by exposure to UV radiation.
7. Pharmaceutical composition, characterized in that it comprises, in a pharmaceutically acceptable support, at least one of the compounds as defined in any of claims 1 to 4.
8. Composition according to claim 7, characterized in that the concentration of compound(s) according to one of claims 1 to 4 is between 0.001% and 5% by weight relative to the composition as a whole.
9. Cosmetic composition, characterized in that it comprises, in a cosmetically acceptable support, at least one of the compounds as defined in any one of claims 1 to 4.
10. Composition according to claim 9, characterized in that the concentration of compound(s) according to one of claims 1 to 4 is between 0.001% and 3% by weight relative to the composition as a whole.
11. Use of a cosmetic composition as defined in either of claims 9 and 10, for body or hair hygiene.
US10/334,978 1996-03-14 2003-01-02 Bicyclic aromatic compounds Abandoned US20030135053A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/334,978 US20030135053A1 (en) 1996-03-14 2003-01-02 Bicyclic aromatic compounds

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR9603235A FR2746101B1 (en) 1996-03-14 1996-03-14 BICYCLIC-AROMATIC COMPOUNDS
FR96/03235 1996-03-14
US08/952,804 US6147255A (en) 1996-03-14 1997-03-05 Bicyclic-aromatic compounds
US09/619,584 US6825360B1 (en) 1996-03-14 2000-07-19 Bicyclic aromatic compounds
US10/334,978 US20030135053A1 (en) 1996-03-14 2003-01-02 Bicyclic aromatic compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/619,584 Continuation US6825360B1 (en) 1996-03-14 2000-07-19 Bicyclic aromatic compounds

Publications (1)

Publication Number Publication Date
US20030135053A1 true US20030135053A1 (en) 2003-07-17

Family

ID=9490195

Family Applications (5)

Application Number Title Priority Date Filing Date
US08/952,804 Expired - Fee Related US6147255A (en) 1996-03-14 1997-03-05 Bicyclic-aromatic compounds
US09/619,584 Expired - Fee Related US6825360B1 (en) 1996-03-14 2000-07-19 Bicyclic aromatic compounds
US09/619,582 Expired - Fee Related US6515021B1 (en) 1996-03-14 2000-09-12 Bicyclic aromatic compounds
US10/252,514 Abandoned US20030060491A1 (en) 1996-03-14 2002-09-24 Bicyclic aromatic compounds
US10/334,978 Abandoned US20030135053A1 (en) 1996-03-14 2003-01-02 Bicyclic aromatic compounds

Family Applications Before (4)

Application Number Title Priority Date Filing Date
US08/952,804 Expired - Fee Related US6147255A (en) 1996-03-14 1997-03-05 Bicyclic-aromatic compounds
US09/619,584 Expired - Fee Related US6825360B1 (en) 1996-03-14 2000-07-19 Bicyclic aromatic compounds
US09/619,582 Expired - Fee Related US6515021B1 (en) 1996-03-14 2000-09-12 Bicyclic aromatic compounds
US10/252,514 Abandoned US20030060491A1 (en) 1996-03-14 2002-09-24 Bicyclic aromatic compounds

Country Status (21)

Country Link
US (5) US6147255A (en)
EP (1) EP0832081B1 (en)
JP (1) JP2991502B2 (en)
KR (2) KR100255418B1 (en)
CN (2) CN100345827C (en)
AT (1) ATE231852T1 (en)
BR (1) BR9702200A (en)
CA (1) CA2218766C (en)
DE (1) DE69718734T2 (en)
DK (1) DK0832081T3 (en)
EA (1) EA001216B1 (en)
ES (1) ES2192668T3 (en)
FR (1) FR2746101B1 (en)
HU (1) HUP9901452A3 (en)
IL (1) IL122196A0 (en)
MX (1) MX9708800A (en)
NO (1) NO975192L (en)
NZ (1) NZ329199A (en)
PL (1) PL187407B1 (en)
PT (1) PT832081E (en)
WO (1) WO1997033881A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015130973A1 (en) * 2014-02-26 2015-09-03 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US9573906B2 (en) 2011-09-15 2017-02-21 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Therapeutic compounds
US10231947B2 (en) 2017-01-23 2019-03-19 Arizona Board Of Regents On Behalf Of Arizona State University Isochroman compounds and methods of use thereof
US10238655B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Dihydroindene and tetrahydronaphthalene compounds
US10238626B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US10328040B2 (en) 2014-01-17 2019-06-25 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic methods

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115728B1 (en) 1995-01-30 2006-10-03 Ligand Pharmaceutical Incorporated Human peroxisome proliferator activated receptor γ
PT859608E (en) * 1995-09-18 2004-06-30 Ligand Pharm Inc NIDDM TREATMENT WITH RXR AGONISTS
FR2746101B1 (en) * 1996-03-14 1998-04-30 BICYCLIC-AROMATIC COMPOUNDS
FR2776657B1 (en) * 1998-03-31 2000-05-26 Cird Galderma BICYCLIC-AROMATIC COMPOUNDS AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETOLOGY
EP1082111A4 (en) * 1998-05-06 2004-03-10 Galderma Res & Dev Assay for identification of compounds that promote melanin production and retinoid-like compounds identified by said assay
US20030113281A1 (en) * 1998-05-06 2003-06-19 Galderma Research & Development, S.N.C. Assay for identification of compounds that promote melanin production and retinoid-like compounds identified by said assay
FR2801307B1 (en) * 1999-11-24 2002-12-06 Galderma Res & Dev VITAMIN D ANALOGS
JP2007297283A (en) * 2004-07-28 2007-11-15 Santen Pharmaceut Co Ltd Novel cinnamic acid related compound
US8293803B2 (en) 2006-08-29 2012-10-23 Reinnervate Limited Retinoid compounds and their use
FR2910321B1 (en) 2006-12-21 2009-07-10 Galderma Res & Dev S N C Snc CREAM GEL COMPRISING AT LEAST ONE RETINOID AND BENZOLE PEROXIDE
FR2910320B1 (en) 2006-12-21 2009-02-13 Galderma Res & Dev S N C Snc EMULSION COMPRISING AT LEAST ONE RETINOID AND BENZOLE PEROXIDE
FR2931661B1 (en) 2008-05-30 2010-07-30 Galderma Res & Dev NOVEL DEPIGMENTING COMPOSITIONS IN THE FORM OF AN ANHYDROUS VASELIN - FREE AND ELASTOMER - FREE COMPOSITION COMPRISING A SOLUBILIZED PHENOLIC DERIVATIVE AND A RETINOID.
JP2013014534A (en) * 2011-07-04 2013-01-24 Daicel Corp Benzoylformic acid compound and method for producing the same
SI23949A (en) 2011-12-19 2013-06-28 Silverstone Pharma The new crystalline salts of zofenopril, the procedure for obtaining them and their use in therapy
KR20150127208A (en) * 2013-03-14 2015-11-16 브리스톨-마이어스 스큅 컴퍼니 Bicyclo [2.2.1] acid gpr120 modulators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5995229A (en) * 1982-11-24 1984-06-01 Tsumura Juntendo Inc Novel hydroxybiphenyl compound
FR2601670B1 (en) * 1986-07-17 1988-10-07 Cird NOVEL AROMATIC BICYCLIC DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR USE IN HUMAN AND VETERINARY MEDICINE AND IN COSMETICS
US4792567A (en) * 1987-06-09 1988-12-20 Fmc Corporation Acaricidal aryl arylthien-2-yl ethenes
US5814651A (en) * 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
FR2719043B1 (en) * 1994-04-26 1996-05-31 Cird Galderma New bicyclic-aromatic compounds, pharmaceutical and cosmetic compositions containing them and uses.
CZ288526B6 (en) * 1994-08-10 2001-07-11 F. Hoffmann-La Roche Ag Derivatives of tetrahydronaphthalene or indane, pharmaceutical preparations based thereon and intermediates for preparing these derivatives
FR2729664A1 (en) * 1995-01-20 1996-07-26 Cird Galderma BICYCLIC-AROMATIC COMPOUNDS WITH HIGH BIOLOGICAL ACTIVITY PHARMACEUTICAL AND COSMETIC COMPOSITIONS IN CONTAINING AND USES
FR2746101B1 (en) * 1996-03-14 1998-04-30 BICYCLIC-AROMATIC COMPOUNDS
ID21538A (en) * 1997-12-19 1999-06-24 Takeda Chemical Industries Ltd ANILIDA DESCRIPTION, PRODUCTION AND USAGE
CN1282243A (en) * 1997-12-19 2001-01-31 武田药品工业株式会社 Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative
US5994379A (en) * 1998-02-13 1999-11-30 Merck Frosst Canada, Inc. Bisaryl COX-2 inhibiting compounds, compositions and methods of use

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9573906B2 (en) 2011-09-15 2017-02-21 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Therapeutic compounds
US10391093B2 (en) 2011-09-15 2019-08-27 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Therapeutic compounds
US10328040B2 (en) 2014-01-17 2019-06-25 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic methods
WO2015130973A1 (en) * 2014-02-26 2015-09-03 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US9908856B2 (en) 2014-02-26 2018-03-06 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US10005741B2 (en) 2014-02-26 2018-06-26 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US10231947B2 (en) 2017-01-23 2019-03-19 Arizona Board Of Regents On Behalf Of Arizona State University Isochroman compounds and methods of use thereof
US10238655B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Dihydroindene and tetrahydronaphthalene compounds
US10238626B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds

Also Published As

Publication number Publication date
ES2192668T3 (en) 2003-10-16
US6147255A (en) 2000-11-14
FR2746101A1 (en) 1997-09-19
FR2746101B1 (en) 1998-04-30
KR100263581B1 (en) 2000-08-01
EP0832081B1 (en) 2003-01-29
US6825360B1 (en) 2004-11-30
KR100255418B1 (en) 2000-05-01
MX9708800A (en) 1998-02-28
JP2991502B2 (en) 1999-12-20
PL187407B1 (en) 2004-07-30
BR9702200A (en) 1999-07-20
ATE231852T1 (en) 2003-02-15
CN1109031C (en) 2003-05-21
PL323364A1 (en) 1998-03-30
DK0832081T3 (en) 2003-05-26
EP0832081A1 (en) 1998-04-01
CN1443756A (en) 2003-09-24
HUP9901452A3 (en) 2001-02-28
US20030060491A1 (en) 2003-03-27
EA001216B1 (en) 2000-12-25
DE69718734D1 (en) 2003-03-06
CN1190394A (en) 1998-08-12
NO975192D0 (en) 1997-11-12
EA199700380A1 (en) 1998-08-27
US6515021B1 (en) 2003-02-04
NO975192L (en) 1998-01-14
NZ329199A (en) 1999-06-29
CA2218766A1 (en) 1997-09-18
WO1997033881A1 (en) 1997-09-18
AU2030597A (en) 1997-10-01
DE69718734T2 (en) 2003-08-21
HUP9901452A2 (en) 1999-08-30
IL122196A0 (en) 1998-04-05
CA2218766C (en) 2003-07-15
PT832081E (en) 2003-06-30
AU704753B2 (en) 1999-05-06
KR19990014804A (en) 1999-02-25
CN100345827C (en) 2007-10-31
JPH10509987A (en) 1998-09-29

Similar Documents

Publication Publication Date Title
US6368608B1 (en) Polyaromatic propynyl compounds and pharmaceutical/cosmetic compositions comprised thereof
US6825360B1 (en) Bicyclic aromatic compounds
US5786379A (en) Adamantyl-substituted biaromatic compounds and pharmaceutical/cosmetic compositions comprised thereof
US6992095B2 (en) Stilbene compounds comprising an adamantyl group, compositions and methods thereof
US6150413A (en) Triaromatic compounds and pharmaceutical/cosmetic compositions comprised thereof
US5705167A (en) Aromatic polyenic compounds and pharmaceutical/cosmetic compositions comprised thereof
US7148245B2 (en) Biphenyl derivatives substituted with an aromatic or heteroaromatic radical, and pharmaceutical and cosmetic compositions containing them
US5981776A (en) Heterocyclic biaryl compounds, pharmaceutical and cosmetic compositions containing them and uses thereof
US20060014803A1 (en) Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics
US5877342A (en) Adamantyl-substituted biaromatic compounds and pharmaceutical/cosmetic compositions comprised thereof
US5766610A (en) Polycyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof
US5849798A (en) Polyaromatic heterocyclic compounds and pharmaceutical/cosmetic compositions comprised thereof
US5985928A (en) Bioactive bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof
US6632963B1 (en) Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof
US6326510B1 (en) Bi-aromatic compounds, compositions containing them and uses
US6313162B1 (en) Propynyl or dienyl biaromatic compounds
US6103762A (en) Bi-aromatic compounds and pharmaceutical and cosmetic compositions containing same
US5723499A (en) Polycyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof
US5935585A (en) Biaromatic amido compounds and pharmaceutical/cosmetic compositions comprised thereof
US6441010B2 (en) Bi-aromatic compounds linked via a heteroethynylene radical, and pharmaceutical and cosmetic compositions containing them
US6057341A (en) Bi-aromatic dibenzofuran derivatives and their use in human and veterinary medicine and in cosmetics
US20030100583A1 (en) Bi-aromatic compounds linked via a heteroethylene radical, and pharmaceutical and cosmetic compositions using them
MXPA97010466A (en) Esthylene compounds containing an adamantile group, compositions that contain them and their u

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION